Document:

<PAGE>

                                                                REDACTED VERSION

                                  EXHIBIT 10.27

                                       TO

                         LIGHT SCIENCES ONCOLOGY, INC.'S

                       REGISTRATION STATEMENT ON FORM S-1

                                 INITIALLY FILED

                                 APRIL 21, 2006

                           REGISTRATION NO. 333-133474

"[ * ]" = omitted, confidential material, which material has been separately
          filed with the Securities and Exchange Commission pursuant to a
          request for confidential treatment.

<PAGE>

                     COMPONENT DEVELOPMENT AND DELIVERABLES
                               SERVICES AGREEMENT

                          DATED AS OF DECEMBER 27, 2001

                                     BETWEEN

                          LIGHT SCIENCES ONCOLOGY, INC.

                                       AND

               AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD.
                (FORMERLY AGILENT TECHNOLOGIES MALAYSIA SDN BHD)

<PAGE>

            COMPONENT DEVELOPMENT AND DELIVERABLES SERVICES AGREEMENT

                                     BETWEEN

                           LIGHT SCIENCES CORPORATION

                                  ("CUSTOMER")

                                       AND

                      AGILENT TECHNOLOGIES MALAYSIA SDN BHD

                                   ("AGILENT")

<PAGE>

TABLE OF CONTENTS

SECTIONS OF THE AGREEMENT

1.   Definitions

2.   AGILENT Obligations

3.   CUSTOMER Obligations

4.   Price and Payment

5.   Change Orders

6.   Acceptance

7.   Warranties

8.   Intellectual Property Rights/Licenses

9.   Intellectual Property Indemnity

10.  Confidential Information

11.  Compliance

12.  Regulatory Response; Inspections

13.  Remedies and Liabilities

14.  Term and Termination

15.  General

EXHIBITS TO THE AGREEMENT

A.   Statement of Work

B.   Change Order Procedures

<PAGE>

This Component Development and Deliverable Services Agreement ("Agreement") is
made between Light Sciences Corporation ("CUSTOMER") having its offices at 1065
12th Ave, NW, Suite E-2, Issaquah, WA 98027, USA, and AGILENT TECHNOLOGIES
MALAYSIA SDN BHD ("AGILENT") and having its registered address at
_____________________ --effective as of 27th December 2001 ("Effective Date").

The purpose of this Agreement is to set forth the mutually agreeable terms and
conditions under which AGILENT will perform Component Development and
Deliverable Services and provide Deliverables to CUSTOMER according to one or
more Statements of Work.

1.   DEFINITIONS

1.1  "COMPONENT DEVELOPMENT AND DELIVERABLES SERVICES" (sometimes referred to as
     "Work") refers to such activities as analysis, design, planning,
     development, consulting, implementation, education, training and project
     management as described in a Statement of Work. Component Development and
     Deliverables Services may also include other types of services described
     more specifically in a Statement of Work.

1.2  "CUSTOMER FIELD OF USE" means the use of [ * ].

1.3  "DELIVERABLES" means the tangible results of the Component Development and
     Deliverables Services provided by AGILENT to CUSTOMER as described in each
     Statement of Work (specifically, for the further development of the Light
     Sciences Corporation Light Bar). Unless otherwise agreed, the term
     Deliverables does not include custom hardware.

1.4  "STATEMENT OF WORK" means a document attached to or referenced by and
     incorporated into this Agreement which describes a specific project,
     engagement or assignment ("Project") for which AGILENT will provide
     Component Development and Deliverables Services to CUSTOMER. More than one
     Statement of Work may be attached to this Agreement from time to time.

1.5  "REQUIREMENTS" means the CUSTOMER supplied design and technical
     information, drawings, concepts, schematics, software and other related
     material, which will be used by AGILENT in the development of the
     Deliverables.

1.6  "PRODUCT SPECIFICATIONS" means the detailed documentation of the design
     considerations, the theory of operations and the specifications of the
     Deliverables.

2.   AGILENT OBLIGATIONS

2.1  AGILENT will use commercially reasonable efforts to perform the Component
     Development and Deliverables Services and provide the Deliverables
     specifically described in one or more Statements of Work in accordance with
     the terms and conditions of this Agreement. CUSTOMER and AGILENT will sign
     a separate Statement of Work for each Project under this Agreement , which
     will be incorporated by reference into this Agreement upon execution by the
     parties. Each Statement of Work will: (i) be made in writing in the form
     attached as Exhibit A, (ii) reference this Agreement, (iii) be numbered
     consecutively on a chronological basis, and (iv) be executed by authorized
     representatives of CUSTOMER and

----------
[ * ] Confidential Treatment Requested

<PAGE>

     AGILENT. Individual Statements of Work should address at least the
following areas:

               Project description
               Price, payment and delivery schedules
               Scope of the Component Development and Deliverables Services
               Acceptance criteria
               Nature of Deliverables
               Project coordination
               Product Specifications

2.2  Unless otherwise agreed, Component Development and Deliverables Services
     will be performed during AGILENT's normal business hours between 8.30am to
     5.30pm, Mondays to Fridays (excluding Saturdays, Sundays and public
     holidays).

2.3  AGILENT will use commercially reasonable efforts to provide the
     Deliverables and perform the Component Development and Deliverables
     Services in accordance with the delivery schedule specified in each
     Statement of Work.

2.4  AGILENT may utilize qualified and reputable subcontractors which are
     obligated under applicable terms and conditions to the same extent as
     AGILENT is obligated under this Agreement and which are pre-approved by
     CUSTOMER in writing to perform Component Development and Deliverables
     Services and/or provide Deliverables.

2.5  AGILENT will appoint a representative to supervise and coordinate AGILENT's
     performance of Component Development and Deliverables Services. AGILENT may
     change its representative at any time upon written notice and approval of
     CUSTOMER.

2.6  Unless otherwise agreed in a Statement of Work, AGILENT is not responsible
     for providing support for any Deliverables.

3.   CUSTOMER OBLIGATIONS

3.1  CUSTOMER will comply with the general obligations specified below together
     with any specific CUSTOMER obligations described in a Statement of Work, in
     a timely manner.

3.2  CUSTOMER acknowledges that AGILENT's ability to deliver the Component
     Development and Deliverables Services may be dependent upon CUSTOMER's full
     and timely cooperation with AGILENT, as well as the accuracy and
     completeness of any information and data CUSTOMER provides to AGILENT.
     Therefore, CUSTOMER will:

     3.2.1 Provide AGILENT limited access to, and use of, certain information,
          data, and documentation, only for and to the extent such access and
          use is necessary for AGILENT to complete the Component Development and
          Deliverables Services under this Agreement and applicable Statement of
          Work.

     3.2.2 Appoint a representative who will provide professional and prompt
          liaison with AGILENT, have the necessary expertise and authority to
          commit CUSTOMER, be available at all times when AGILENT's personnel
          are at the CUSTOMER's site (or designate an alternate with the same
          level

<PAGE>

          of authority in the event of unavailability caused by illness or other
          valid reasons), and meet with the AGILENT representative at regular
          intervals to be agreed upon to review progress and resolve any issues
          relating to the Component Development and Deliverables Services or
          Deliverables.

3.3  CUSTOMER will be responsible for maintaining an external procedure for
     reconstruction of lost or altered files, data or programs to the extent
     deemed necessary by CUSTOMER, and for actually reconstructing any such
     materials to the extent such loss or alteration is caused by CUSTOMER.

3.4  CUSTOMER will be liable for any delays to the delivery schedule specified
     in each Statement of Work caused by CUSTOMER or resulting from CUSTOMER's
     failure to fulfill any of its obligations. AGILENT may charge Customer for
     commercially reasonable additional charges incurred by AGILENT directly
     related to the Project as a result of such delays, and may reasonably
     adjust the affected delivery schedule accordingly.

3.5  Upon AGILENT'S receipt of written acceptance set forth in Section 6.1,
     CUSTOMER will be responsible at all times for the supervision, management
     and control of the Deliverables and any results obtained from the
     Deliverables, including without limitation all responsibility for
     maintenance of proper machine configuration, audit controls, operating
     methods, error detection and recovery procedures, back-up plans, security,
     insurance, maintenance and all other activities necessary to enable
     Customer to use the Deliverables.

4.   PRICE AND PAYMENT

4.1  Prices for Component Development and Deliverables Services and Deliverables
     will be specified in each Statement of Work.. Prices include all materials
     and labor expenses, but do not include withholding, sales, use, service,
     value added or like taxes, or customs duties. AGILENT will state separately
     on its invoices any sales or other taxes or custom duties that (i) are owed
     by CUSTOMER solely as a result of entering into this Agreement and the
     payment of the fees hereunder, (ii) are required to be collected from
     CUSTOMER by AGILENT under applicable law, and (iii) are based solely upon
     the amounts payable under this Agreement. CUSTOMER will remit such taxes to
     AGILENT with its payment of the respective invoice, whereupon AGILENT will
     provide CUSTOMER with official tax receipts indicating that such taxes have
     been paid by AGILENT. However, CUSTOMER may provide AGILENT with an
     exemption certificate (including, without limitation, a resale
     certificate), in which case AGILENT will not collect the taxes covered by
     such certificate.

4.2  AGILENT will issue invoices in accordance with the payment schedule
     specified in each Statement of Work. Charges for travel expenses which have
     been pre-authorized by CUSTOMER in writing may be invoiced separately.
     CUSTOMER will pay all invoices within [ * ] days from the receipt of
     invoice. AGILENT may change credit terms upon reasonable notice at any time
     when CUSTOMER's financial condition, previous payment record, or the nature
     of CUSTOMER's relationship with AGILENT so warrants.

4.3  Should any sum due to AGILENT remain unpaid after [ * ] days from the date
     of invoice receipt, AGILENT may terminate this Agreement pursuant to
     Section 14.2.2 and discontinue performance under any other agreement with
     CUSTOMER.

----------
[ * ] Confidential Treatment Requested

<PAGE>

5.   CHANGE ORDERS

5.1  "Change Order" means an agreed upon change or modification to the
     Deliverables, Component Development and Deliverables Services or other
     material aspect of a Statement of Work that complies with the requirements
     of Exhibit B. Requests by CUSTOMER and recommendations by AGILENT for
     Change Orders are subject to the procedures set forth in Exhibit B, and
     will be made in writing in the form attached to Exhibit B and will be
     attached and incorporated into this Agreement as an Attachment to this
     Agreement.

5.2  All Change Orders must be mutually agreed by the parties and comply with
     Section 5.1. Pending such agreement, AGILENT will continue to perform and
     be paid as if such Change Order had not been requested or recommended,
     provided that if either party proposes a Change Order which, in AGILENT's
     judgment, represents a material change in the Component Development and
     Deliverables Services or Deliverables and such Change Order remains
     outstanding for [ * ] days or is rejected by CUSTOMER, AGILENT will have
     the right to terminate the affected Statement of Work pursuant to Section
     14.2.2 below.

6.   ACCEPTANCE

6.1  AGILENT will provide notice to CUSTOMER when the Deliverables are ready for
     acceptance. Acceptance of Deliverables will occur upon the earlier of: a)
     the date AGILENT demonstrates to CUSTOMER, by the successful completion of
     acceptance tests, or that the Deliverables substantially conform to the
     acceptance criteria specified in the applicable Statement of Work; or b)
     the date that CUSTOMER uses any substantial part of the Deliverables for
     any purpose other than performing acceptance tests. Acceptance of Component
     Development and Deliverables Services will occur upon AGILENT's performance
     of such Component Development and Deliverables Services and CUSTOMER's
     acknowledging of its acceptance of such performance in writing.

6.2  In the event that any Deliverable fails to conform to the acceptance
     criteria specified in the applicable Statement of Work or Product
     Specifications, or otherwise do not comply with other provisions of this
     Agreement, AGILENT will have a reasonable time to remedy such substantial
     non-conformance, following AGILENT's receipt of written notice from
     CUSTOMER specifying in reasonable detail the nature of such
     non-conformance. In the event that AGILENT is unable to remedy the
     non-conformance: a) CUSTOMER may accept the Deliverable without warranty,
     on an "AS IS" basis, subject to an agreed upon price adjustment; or b)
     CUSTOMER may return the Deliverable to AGILENT and receive a refund of
     amounts paid to AGILENT for the Deliverable. All non-conforming
     Deliverables returned by CUSTOMER to AGILENT and all replacements shipped
     by AGILENT to CUSTOMER therefore will be at AGILENT'S risk and expense.

6.3  If acceptance testing is delayed for reasons attributable to CUSTOMER,
     acceptance will be deemed to occur on the [ * ] day after notice by AGILENT
     that the Deliverable is ready for acceptance testing.

7.   WARRANTIES

7.1  AGILENT warrants that it will perform Component Development and
     Deliverables Services in

----------
[ * ] Confidential Treatment Requested

<PAGE>

     accordance with generally recognized commercially reasonable practices and
     standards and all Deliverables will comply with the Specifications provided
     by CUSTOMER and all other mutually-agreed requirements. Upon CUSTOMER's
     request, AGILENT will re-perform any Component Development and Deliverables
     Services not performed in accordance with the foregoing warranty, provided
     that AGILENT receives notice from CUSTOMER within [ * ] days after such
     Component Development and Deliverables Services were performed in
     accordance with Section 6.2.

7.2  AGILENT further warrants that Deliverables will not be defective in
     material or defective workmanship during the Term and will conform to the
     acceptance criteria and within tolerances of all Product Specifications as
     specified in the applicable Statements of Work for a period of [ * ] days
     from the date of acceptance

7.3  AGILENT does not warrant that the operation of Deliverables will be
     uninterrupted or error free or conform to any reliability or performance
     standards beyond those specified in the applicable acceptance criteria or
     applicable Product Specifications. AGILENT also does not warrant that
     Deliverables will be compatible with future AGILENT products or those of
     other vendors.

7.4  If AGILENT receives notice during the warranty period of any
     non-conformance with the acceptance criteria or Specifications, that
     materially impairs the functioning of a Deliverable, AGILENT will replace
     the Deliverable without additional charge or, at CUSTOMER's request and
     direction, correct such non-conformance or provide a remedy which
     substantially corrects the non-conformance.

7.5  If AGILENT is unable within a reasonable time to comply with the foregoing
     obligations, AGILENT will refund the paid price stated in the Statement of
     Work upon prompt return of the affected Deliverable to AGILENT, and/or
     delivery to AGILENT of proof of the destruction of the affected
     Deliverable.

7.6  The warranties provided in this Section 7 will not apply in the event of
     deemed acceptance under Sections 6.1, 6.2 or 6.3above, or to defects or
     non-conformances resulting from:

     7.6.1 Unauthorized, improper or inadequate maintenance or calibration by
          CUSTOMER or any third party.

     7.6.2 Software, hardware, interfacing, or supplies not supplied by AGILENT.

     7.6.3 Unauthorized modification of Deliverables or any portion thereof.

     7.6.4 Improper use or operation of Deliverables or any portion thereof or
          CUSTOMER's failure to comply with the applicable environmental
          specification.

     7.6.5 Improper site preparation or maintenance by CUSTOMER or a third
          party.

7.7  THE ABOVE WARRANTIES ARE EXCLUSIVE AND NO OTHER WARRANTY, WHETHER WRITTEN
     OR ORAL, IS EXPRESSED OR IMPLIED. AGILENT SPECIFICALLY DISCLAIMS THE
     IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

----------
[ * ] Confidential Treatment Requested

<PAGE>

8    INTELLECTUAL PROPERTY RIGHTS/LICENSES

8.1  All copyrights and other intellectual property rights existing prior to the
     Effective Date ("Pre-Existing Intellectual Property") will belong to the
     party that owned such rights immediately prior to the Effective Date.

8.2  Neither party will gain by virtue of this Agreement any rights of ownership
     of copyrights, patents, trade secrets, trademarks or any other intellectual
     property rights owned by the other.

8.3  The parties agree that ownership of any and all inventions, discoveries,
     and original works of authorship (including, without limitation, ideas,
     know-how, data, information, documentation, formulae, results, prototypes,
     designs, methods and procedures), and all intellectual property rights in
     the foregoing, whether or not patentable, which are expressed in a tangible
     medium, conceived, and/or reduced to practice (hereinafter "INVENTIONS"),
     by any of either party's employees or independent contractors or
     sub-contractors in the course of performance of work in connection with
     this Agreement or any applicable Statement of Work during the term of this
     Agreement (hereinafter "INVENTORS") will be owned by the party whose
     employees, or independent contractors or subcontractors expressed in a
     tangible medium, conceived, and reduced to practice such Inventions. If
     employees, or independent contractors or subcontractors of both parties
     expressed in a tangible medium, conceived, and reduced to practice such
     Inventions then the parties will jointly own the Inventions as joint
     tenants.

8.4  Copyright/Work for Hire. To the extent any deliverables, including, but not
     limited to, specifications, schematics, designs, prototypes, products,
     software code, documentation, reports, memoranda, studies, plans, exhibits,
     or other materials prepared by AGILENT in the performance of services under
     this Agreement, include material subject to copyright protection, such
     materials have been specially commissioned by CUSTOMER for use as a
     contribution to a collective work and they shall be deemed "work for hire"
     as such term is defined under U.S. copyright law. Provided AGILENT assigns
     all right and title to CUSTOMER, [ * ].

8.5  AGILENT grants CUSTOMER an option to [ * ].

8.6  CUSTOMER grants AGILENT a limited non-exclusive, worldwide, royalty-free,
     non-assignable, nontransferable license to use, copy, make derivative works
     of, distribute, display, perform, and transmit CUSTOMER's pre-existing
     copyrighted works, other Pre-Existing Intellectual Property rights and
     materials as CUSTOMER may provide to AGILENT during the Term of this
     Agreement solely to the extent necessary for AGILENT to perform its
     obligations under this Agreement or any applicable Statement of Work.
     AGILENT will not sublicense, reverse engineer, disassemble or decompile any
     CUSTOMER Pre-Existing Intellectual Property or materials.

8.7  AGILENT will promptly disclose in writing to CUSTOMER any Inventions and
     all pertinent information related thereto within [ * ] of authoring,
     conceiving, otherwise generating, and the actual reduction to practice such
     Invention, and will provide CUSTOMER with copies of any patent application
     fourteen [ * ] prior to the filing thereof in sufficient detail to
     determine inventorship.

8.8  Subject to the ownership rights of the parties in Section 8.3, CUSTOMER
     will own all right, title, and interest, , in and to CUSTOMER'S proprietary
     materials, the prototypes, or other materials provided to or

----------
[ * ] Confidential Treatment Requested

<PAGE>

     developed by AGILENT under this Agreement,, and as well as the Deliverables
     provided under this Agreement or applicable Statement of Work.

8.9  Co-operation. Each party will execute any necessary documents and otherwise
     assist the other, at the other's expense, as reasonably requested by the
     other, to protect the other's Intellectual Property Rights and rights
     therein provided under this Section 8.

8.10 No Implied Rights Granted. No license under any patent or copyright now or
     hereafter obtained is granted, agreed to be granted, or implied by this
     Agreement, other than as expressly specified in the Section 8.

9.   INTELLECTUAL PROPERTY INDEMNITY

9.1  AGILENT will defend or settle any claim against CUSTOMER regarding the
     Component Development and Deliverable Services and Deliverables, which
     alleges that AGILENT knowingly infringed a patent, utility model,
     industrial design, copyright, trade secret, mask work or trademark in the
     country where such Deliverables are used or such Component Development and
     Deliverables Services are provided.

9.2  The indemnities provided in Section 9.1 above will apply provided CUSTOMER
     promptly notifies AGILENT in writing of the claim, and CUSTOMER cooperates
     with AGILENT in and grants AGILENT sole control of the defense or
     settlement.

9.3  For infringement claims covered by this Section 9, AGILENT will pay
     infringement claim defense costs, settlement amounts and court-awarded
     damages. If such a claim regarding a Deliverable appears likely, AGILENT
     may modify the Deliverable, procure any necessary license or replace it. If
     AGILENT determines that none of these alternatives is reasonably available,
     AGILENT will refund CUSTOMER's purchase price upon return of the
     Deliverable if within one year of delivery, or CUSTOMER's net book value
     thereafter.

9.4  AGILENT has no obligation for any claim of infringement arising from:

     9.4.1 AGILENT's strict compliance with or use of CUSTOMER's information,
          technology, designs, specifications or instructions, including those
          incorporated into any Statement of Work.

     9.4.2 Modification of a Deliverable by CUSTOMER or a third party.

     9.4.3 Use of a Deliverable in a way not indicated in a Statement of Work.

     9.4.4 Use of a Deliverable with products not supplied by AGILENT.

9.5  Sections 9.1-9.4 states AGILENT's entire indemnification liability for
     claims of intellectual property infringement.

9.6  AGILENT's Intellectual Property indemnification obligations set forth in
     Sections 9.1-9.3 shall not apply to Intellectual Property infringement
     claims which arise from AGILENT's strict compliance with the Requirements.

9.7  CUSTOMER will defend or settle any claim against AGILENT regarding the
     Requirements, which alleges that CUSTOMER knowingly infringed a patent,
     utility model, industrial design, copyright, trade secret, mask work or
     trademark in the country where such Requirements are used, as long as
     AGILENT

<PAGE>

     exercises reasonable care in providing Component Development and
     Deliverables Services under this Agreement so as not to infringe such
     rights.

9.8  The indemnities provided in Section 9.7 above will apply provided AGILENT
     promptly notifies CUSTOMER in writing of the claim, and AGILENT cooperates
     with CUSTOMER in and grants CUSTOMER sole control of the defense or
     settlement.

9.9  For infringement claims covered by Section 9.7, CUSTOMER will pay
     infringement claim defense costs, settlement amounts and court-awarded
     damages. If such a claim regarding a Requirement appears likely, CUSTOMER
     may modify the Requirement, procure any necessary license or replace it.

9.10 CUSTOMER has no obligation for any claim of infringement arising from:

     9.10.1 CUSTOMER 's strict compliance with or use of AGILENT 's information,
          technology, or designs, including those incorporated into any
          Statement of Work.

     9.10.2 Modification of a Requirement by AGILENT or a third party.

     9.10.3 Use of a Requirement in a way not indicated in a Statement of Work.

     9.10.4 Use of a Requirement with products not supplied by CUSTOMER.

9.11 Sections 9.7-9.9 state CUSTOMER 's entire indemnification liability for
     claims of intellectual property infringement.

10.  CONFIDENTIAL INFORMATION

10.1 During the term of this Agreement, either party may receive or have access
     to technical information, as well as information about product plans and
     strategies, promotions, customers and related non-technical business
     information which the disclosing party considers to be confidential
     ("Confidential Information"). In the event such Confidential Information is
     disclosed, the parties shall first agree to disclose and receive such
     information in confidence. If then disclosed, the Confidential Information
     shall be marked as confidential at the time of disclosure, or if disclosed
     orally but stated to be confidential, shall subsequently be designated as
     confidential in writing by the disclosing party summarizing the
     Confidential Information disclosed and sent to the receiving party within a
     reasonable period of time.

10.2 Confidential Information may be used by the receiving party only with
     respect to the performance of its obligations under this Agreement, and
     only by those employees of the receiving party and its subcontractors who
     have a need to know such information for purposes related to this
     Agreement, provided that such subcontractors have signed separate
     agreements containing substantially similar confidentiality provisions. The
     receiving party shall protect the Confidential Information of the
     disclosing party by using the same degree of care (but not less than a
     reasonable degree of care) to prevent the unauthorized use, dissemination
     or publication of such Confidential Information, as the receiving party
     uses to protect its own confidential information of like nature. The
     receiving party's obligation under this Section shall be for a period of
     [ * ] after the date of disclosure.

10.3 The obligations stated in this Section shall not apply to any information
     which is:

----------
[ * ] Confidential Treatment Requested

<PAGE>

     10.3.1 Already known by the receiving party prior to disclosure;

     10.3.2 Publicly available through no fault of the receiving party;

     10.3.3 Rightfully received from a third party without a duty of
          confidentiality;

     10.3.4 Disclosed by the disclosing party to a third party without a duty of
          confidentiality on such third party;

     10.3.5 Independently developed by the receiving party prior to or
          independent of the disclosure;

     10.3.6 Disclosed under operation of law;

     10.3.7 Disclosed by the receiving party with the disclosing party's prior
          written approval.

11.  COMPLIANCE.

11.1 AGILENT Compliance. AGILENT agrees to comply with all federal, state,
     local, and foreign laws, rules, requirements, and regulations applicable to
     its performance of this Agreement pertaining to a manufacturer of
     semiconductor products.

11.2 CUSTOMER Compliance. CUSTOMER understands that it is responsible for
     compliance with all laws, rules, and regulatory requirements that
     specifically apply to a manufacturer of medical devices

12.  REGULATORY RESPONSE; INSPECTIONS.

12.1 Regulatory Response. In the event of Governmental Authority inquiry
     concerning Component Development and Deliverables Services, AGILENT agrees
     to cooperate with CUSTOMER in response thereto, including, but not limited
     to, supplying information about the production, testing and assembly of all
     Deliverables to CUSTOMER upon reasonable notice.

12.2 Audits. During the term of this Agreement, AGILENT will permit CUSTOMER's
     representatives, or its designate, to examine or audit AGILENT's
     performance of the Services and AGILENT's facilities at which the services
     are conducted upon reasonable advance notice during regular business hours
     to determine that the Services are being conducted in accordance with this
     Agreement, including the applicable Statement(s) of Work, the facilities
     are adequate, and the Services comply with all applicable laws and
     regulations.

12.3 Records. AGILENT retain or provide to CUSTOMER hard copies for a period up
     to [ * ] from the date of production of all Light Bars supplied by AGILENT
     to CUSTOMER, or for any period less than [ * ] as otherwise instructed by
     CUSTOMER.

13.  REMEDIES AND LIABILITIES

13.1 The remedies in this Agreement are CUSTOMER's sole and exclusive remedies.

13.2 TO THE EXTENT AGILENT IS HELD LEGALLY LIABLE TO CUSTOMER, AGILENT'S
     LIABILITY IS LIMITED TO:

     13.2 1 [ * ].

----------
[ * ] Confidential Treatment Requested

<PAGE>

     13.2 2 DAMAGES FOR BODILY INJURY.

     14.2 3 DIRECT DAMAGES TO TANGIBLE PROPERTY UP TO A LIMIT OF U.S. [ * ].

     13.2.4 OTHER DIRECT DAMAGES FOR ANY CLAIM BASED ON A MATERIAL BREACH OF ANY
          OTHER TERM OF THIS AGREEMENT, UP TO A MAXIMUM OF US [ * ] OR THE
          AMOUNTS PAID TO AGILENT UNDER THIS AGREEMENT, WHICHEVER IS [ * ].

13.3 Notwithstanding Section 13.2 above, in no event will AGILENT or its
     affiliates, subcontractors and suppliers be liable for any of the
     following:

     13.3.1 Actual loss or direct damage that is not listed in Section 13.2
          above.

     13.3.2 Damages for loss of data, or Software restoration.

     13.3.3 Damages relating to CUSTOMER's procurement of substitute products or
          services (i.e., "cost of cover").

     13.3.4 Incidental, special or consequential damages, including downtime
          costs or lost profits but excluding damages for bodily injury and
          payments described in Section 13.2 above.

13.4 The Deliverables are not specifically designed, manufactured or intended
     for sale as parts, components or assemblies for the planning, construction,
     maintenance, or direct operation of a nuclear facility. CUSTOMER will be
     solely liable if any Deliverables purchased or licensed by CUSTOMER are
     used for these applications. CUSTOMER will indemnify and hold AGILENT
     harmless from all loss, damage, expense or liability in connection with
     such use.

13.5 Sections 13.1-13.3 shall not apply to any liability or obligation under
     Sections 9., 10. or 11.

14.  TERM AND TERMINATION

14.1 This Agreement will commence on the Effective Date and will [ * ].
     Individual Statements of Work will be effective upon execution by both
     parties and will continue in force until both parties have fulfilled all of
     their Project obligations, or until the earlier termination of such
     Statement of Work according to the terms of this Agreement.

14.2 This Agreement or an individual Statement of Work may be terminated
     immediately upon notice in writing:

     14.2.1 By either party if the other party is in material breach of any of
          its obligations hereunder and fails to remedy such breach within [ * ]
          days of receipt of a written notice by the other party which specifies
          the material breach.

     14.2.2 By AGILENT, in the absence of mutual agreement regarding a Change
          Order which represents a material change under Section 5.2, or if
          CUSTOMER fails to pay any sums due under this Agreement within the
          [ * ] day time period specified in Section 4.3.

----------
[ * ] Confidential Treatment Requested

<PAGE>

     14.2.3 By either party if the other party has a receiver appointed, or an
          assignee for the benefit of creditors, or in the event of any
          insolvency or inability to pay debts as they become due by the other
          party, except as may be prohibited by applicable bankruptcy laws.

14.3 Either party may terminate this Agreement for convenience upon [ * ] months
     prior written notice to the other party. Any termination of this Agreement
     will not relieve either party of its obligations under any Statement of
     Work in effect on the date of termination of this Agreement, unless
     otherwise mutually agreed to in writing.

14.4 Upon termination of any Statement of Work, CUSTOMER will pay AGILENT for
     all Work performed and charges and expenses incurred by AGILENT which have
     been pre-approved by CUSTOMER up to the date of termination, and CUSTOMER
     will receive all work in progress for which CUSTOMER has paid. Should the
     sum of such amounts be less than any advance payment received by AGILENT,
     AGILENT will refund the difference within [ * ] days of receipt of an
     invoice from CUSTOMER.

14.5 Sections 4, 7, 8, 9, 10, 12 and 13 above, and Section 15 below, will
     survive termination of this Agreement.

15.  GENERAL

15.1 STANDARD PRODUCTS. This Agreement does not cover standard AGILENT hardware
     and software products sold or licensed to CUSTOMER. Any such transactions
     will be governed by the terms of CUSTOMER's AGILENT purchase agreement or,
     in the absence of a signed purchase agreement, AGILENT's Terms and
     Conditions of Sale and Service (Exhibit E16).

15.2 HEALTH AND SAFETY. AGILENT and any of its subcontractors will, when at the
     CUSTOMER's site, conduct their activities so that their equipment, working
     conditions and methods are safe and without risk to health for their own
     and CUSTOMER's employees, agents or independent contractors as well as for
     any other users of the CUSTOMER's site.

15.3 NON-RESTRICTIVE RELATIONSHIP. AGILENT may provide related or similar
     Component Development and Deliverable Services and Deliverables to other
     customers, except to the extent that such other customers conduct business
     the same, similar or related Field of Use of CUSTOMER.

15.4 NO PUBLICITY. Neither party will publicize or disclose to any third party
     without the consent of the other party, either the price or other terms of
     this Agreement or the fact of its existence and execution, except as may be
     necessary to comply with other obligations stated in this Agreement and
     except to the extent that CUSTOMER may disclose the terms of this Agreement
     to its legal counsel and to potential investors which have executed
     appropriate Confidential Disclosure Agreements.

15.5 NO JOINT VENTURE. Nothing contained in this Agreement will be construed as
     creating a joint venture, partnership or employment relationship between
     the parties hereto, nor will either party have the right, power or
     authority to create any obligation or duty, express or implied, on behalf
     of the other.

----------
[ * ] Confidential Treatment Requested

<PAGE>

15.6 NO ASSIGNMENT. Except with respect to AGILENT's rights regarding the use of
     authorized subcontractors, neither party may assign any rights or
     obligations under this Agreement or any Statement of Work without the prior
     written consent of the other party.

15.7 EXPORT ADMINISTRATION REGULATIONS. If CUSTOMER exports any Deliverable
     outside the country in which the Deliverable is delivered to CUSTOMER,
     CUSTOMER assumes responsibility for complying with applicable laws and
     regulations and for obtaining required export and import authorizations.
     CUSTOMER will not export or re-export any technical data in violation of
     U.S. Export Administration regulations or other applicable export
     regulations.

15.8 FORCE MAJEURE. Neither party will be liable for performance delays or for
     non-performance due to causes beyond its reasonable control.

15.9 NOTICES. All notices required under or regarding this Agreement or any
     individual Statement of Work will be in writing and will be considered
     given upon personal delivery of a written notice to the AGILENT
     representative or CUSTOMER representative designated in the Statement of
     Work, or within five days of mailing, postage prepaid and appropriately
     addressed.

15.10 WAIVER. Neither party's failure to exercise any of its rights under this
     Agreement will constitute or be deemed a waiver or forfeiture of those
     rights.

15.11 SEVERABILITY. If any term or provision of this Agreement is held to be
     illegal or unenforceable, the validity or enforceability of the remainder
     of this Agreement will not be affected.

15.12 EXHIBITS. The following documents are attached hereto as exhibits, the
     terms of which are incorporated by reference in their entirety:

     A    Statement of Work (and all subsequently executed Statements of Work)

     B    Change Order Procedures

15.13 PRECEDENCE. In the event of conflict between the provisions of this
     Agreement and any Statement of Work or Change Order, the provisions of this
     Agreement will to the extent of such conflict take precedence.

15.14 ENTIRE AGREEMENT. This Agreement, and the Agreement's exhibits and
     Statements of Work constitute the entire agreement between AGILENT and
     CUSTOMER for Component Development and Deliverables Services provided
     during the Term supersedes any prior or contemporaneous communications,
     representations or agreements between the parties, whether oral or written,
     regarding the subject matter of this Agreement. CUSTOMER's additional or
     different terms and conditions will not apply. The terms and conditions of
     this Agreement may not be changed except by an amendment signed by an
     authorized representative of each party.

15.15 GOVERNING LAW. This Agreement shall be governed by and construed in
     accordance with the laws of New York, USA.

<PAGE>

SIGNED FOR AND ON BEHALF OF             SIGNED FOR AND ON BEHALF OF

CUSTOMER                                AGILENT TECHNOLOGIES

                                        MALAYSIA SDN BHD

By: /s/ Albert A. Luderer               By: /s/ Lee Soo Ghee
    ---------------------------------       ------------------------------------
Name: Albert A. Luderer, Ph.D.          Name: Lee Soo Ghee
Title: President and CEO                Title: WW OBU Manager

LIGHT SCIENCES CORPORATION              AGILENT TECHNOLOGIES MALAYSIA<PAGE>
                                                                REDACTED VERSION

                                  EXHIBIT 10.28

                                       TO

                         LIGHT SCIENCES ONCOLOGY, INC.'S

                       REGISTRATION STATEMENT ON FORM S-1

                                 INITIALLY FILED

                                 APRIL 21, 2006

                           REGISTRATION NO. 333-133474

"[ * ]" = omitted, confidential material, which material has been separately
          filed with the Securities and Exchange Commission pursuant to a
          request for confidential treatment.

<PAGE>

                       INDIVIDUAL PROJECT AGREEMENT NO. 3

                            DATED AS OF MARCH 8, 2006

                                     BETWEEN

                          LIGHT SCIENCES ONCOLOGY, INC.

                                       AND

                         ERGOMED CLINICAL RESEARCH, LTD.

<PAGE>

                                   APPENDIX G
                         INDIVIDUAL PROJECT AGREEMENT #3

This Individual Project Agreement #3 ("IPA") is entered into pursuant to the
Master Services Agreement, effective February 27, 2004 by and between Light
Sciences Oncology, Inc., a corporation organized under the laws of the state of
Washington, USA, with its principal place of business at 3491 SE Douglas Street,
Suite 250, Snoqualmie, WA 98065 USA ("LSO" or "Sponsor"), and Ergomed Clinical
Research, Ltd., a corporation organized under the laws of United Kingdom, with
its principal place of business at 1 Frederick Sanger Rd., Surrey Research Park,
Guildford, Surrey, GU2 7YD, U.K., ("Contractor").

RECITALS

Whereas Light Sciences Corporation assigned the Master Services Agreement,
effective February 27, 2004, to Light Sciences Oncology on October 5, 2005.

Whereas LSO and Contractor desire to enter into another IPA.

For good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties agree as follows:

     A.  PROJECT TITLE:

A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and
Efficacy of Treating Colorectal Cancer Patients with Recurrent Liver Metastases
using the Litx(TM) plus Chemotherapy as Compared to Chemotherapy Only (the
"Protocol"), attached hereto as Appendix G-1.

     B.  SCOPE OF WORK:

Contractor will perform clinical research organization Services in Austria,
Croatia ,Czech Republic, Germany, Hungary, Italy, Poland, Romania, Serbia,
Slovak Republic, Slovenia, Sweden, Ukraine and USA for the benefit of LSO as
described in this IPA, and all appendices hereto, to manage the clinical trials
conducted under the Protocol (as amended from time to time) as described by this
IPA.

     C.  TIMELINE AND DELIVERABLES:

The term of this IPA commences upon execution and continues until all Services
described by this IPA are completed, unless either the IPA or the Agreement is
terminated early in accordance with the terms and conditions of the Agreement.
LSO and Contractor will review the timeline, progress against deliverables at
least every [ * ] during the term of this IPA.

-------------

    [ * ] Confidential Treatment Requested

<PAGE>

     D.  PROJECT DESCRIPTION/TASKS:

Recruitment Strategies

Contractor will be responsible for pre-screening and qualifying potential Study
sites as requested by Sponsor.

Regulatory Approval/Permits

Contractor will file all appropriate documents with the applicable regulatory
authorities and secure approvals for conducting clinical studies in the
countries which will be selected upon completion of the feasibility assessment
with the approval of the Sponsor. Sponsor will provide any reasonable documents
required for these submissions in a timely manner. Contractor will secure
appropriate permits for the import of investigational drugs and devices to the
clinical sites.

Study Management

Contractor is responsible for the day to day management of the Study including
the project schedules, budgets, regulatory issues, and overall Study progress.
The Ergomed Project Manager, [ * ] will be the primary contact point for
Sponsor. The Ergomed Project Manager is responsible for the management of the
studies and will ensure that the studies are performed to the highest quality
and according to All Applicable Laws and Regulations and to the timelines
outlined below.

The Ergomed Project Manager will update the Light Sciences Project Manager,
Nancy Glaser, during the set up phase on the status of the approval processes
and on the recruitment on a weekly basis in order to ensure that any issues are
highlighted and resolved quickly.

Clinical Site Study Agreements

Contractor shall enter into Clinical Study Agreements ("CSAs") with the
Institutions and / or Investigators, as applicable, as the contracting party,
with each site approved by LSC to conduct the Study. Contractor shall use the
template attached as Appendix G-2 as the form of the contract. Any contract with
the Institution and / or Investigator which substantially deviates from the
template from Appendix G-2 shall be pre-approved in writing by Sponsor before it
is executed. Contractor shall use commercially best efforts to negotiate the
lowest reasonable study budgets and contractual terms and conditions with all
Study sites and Investigators. Contractor will also be responsible for
administering payments to the study sites and Investigators during the course of
the study. The parties will treat investigator grants, as well as all direct
costs, as pass-through costs with no surcharges or fees applied.

------------

    [ * ] Confidential Treatment Requested

<PAGE>

Monitoring

Contractor will comply with the Contractor SOPs concerning site initiation,
routine Monitoring and Close Down visits in the provision of Services under this
IPA as well as All Applicable Laws and Regulations in the provision of services
under this IPA.

     a.        Patient Eligibility Confirmation. Contractor will carefully
               review each patient's signed consent form and primary medical
               records to confirm that the patient satisfies all of the
               inclusion and exclusion criteria during the recruitment phase to
               ensure patient eligibility of patients enrolled and that such
               patients can be accurately evaluated. Sponsor will assign patient
               identification numbers upon Contractor's request.

     b.        Case Report Forms ("CRFs"). Contractor will verify CRFs against
               appropriate source documentation to ensure completion, accuracy
               and consistency of the CRFs, retrieve completed CRFs from study
               sites and forward the completed CRFs to the Sponsor or its
               designate for data entry and analysis.

     c.        Request product shipment to study sites. Contractor will be
               authorized to request product shipment to the individual study
               sites after the required regulatory documents have been reviewed
               by Contractor and Sponsor.

     d.        Adverse Event Reporting/Data Management. Contractor will assure
               that all adverse experiences are being reported accurately and
               appropriately according to Sponsor's direction and in compliance
               with All Applicable Laws, Rules and Regulations. Contractor is
               responsible for all data management and all Serious Adverse Event
               reporting, including write-up of CIOMS and maintenance of the
               safety database, as well as performing two interim analyses of
               the data and writing a report for Sponsor.

     e.        Regulatory Compliance. Contractor will comply with all Applicable
               Laws and Regulations in performance of Services under this IPA

     f.        Communication.  Contractor will maintain regular, frequent
               contact with all study sites and will maintain a communication
               log. Contractor will transmit the communication log to Sponsor
               weekly.

     g.        SDV.  Contractor will perform one hundred percent (100%) Source
               Document Verification (SDV) on all Study data, including patient
               eligibility and all SAEs.

<PAGE>

     h.        Proposed Monitoring Schedule. Contractor will comply with the
               following Monitoring Schedule:

<TABLE>
<CAPTION>

               TASK                                                               TIMELINES
               <S>                                                                <C>
               Frequency of monitoring/telephone contacts                            Weekly
               Timelines for production and review of monitoring report              2 weeks
               Timelines for close down visit following last patient's last
               visit ("LPLV")                                                        1 Week
</TABLE>

      i.       Contractor will conduct the following Study site visits
               (including all sites):

<TABLE>
<CAPTION>

               VISIT TYPE                    NUMBER OF VISITS
               <S>                           <C>

               Feasibility Assessment        70
               Qualification                 60
               Initiation                    50
               Monitoring                    1200
               Close Down                    50
               Total                         1430
</TABLE>

        j.     Quality Assurance.  Contractor will utilize an Independent
               Quality Assurance Manager to perform Study site audits where
               required or upon Sponsor request. The audit report will be
               forwarded to Sponsor for review and discussion prior to sign-off.

        k.     Contractor will provide a full list of all Contractor SOPs to
               Sponsor and will make available for review in the Contractor's
               offices specific SOPs to Sponsor upon request.

Communication/Project Tracking

Contractor shall send Sponsor regular email communication summarizing site
visits, patient enrollment status, CRF retrieval data and key issues and actions
to be taken. In addition, every month a report will be sent to Sponsor which
will include an updated Gantt chart, the contents of which shall be mutually
agreed upon, the budget, site status, patient enrollment activities, SAE
reconciliation, all visit and telephone contact reports.

Task Description

See Appendix G-3.

<PAGE>

     E.      PROJECT BUDGET:

See Appendix G-3.

     F.      APPROVED EXPENSES:

See Appendix G-3.

     G.      MILESTONE PAYMENTS/PREPAYMENTS:

Four milestone payments will be made, in addition to the payment of regular
monthly invoices:

1. [ * ]
2. [ * ]
3. [ * ]
4. [ * ]

The total of these [ * ]. Payments 2.-4. will be made pursuant to the procedure
described in Section 7 of the Master Services Agreement.

     H.      EXPECTED STAFFING LEVEL REQUIREMENTS/SUBCONTRACTORS:

The Contractor's clinical operations team for this IPA include the following:

1. [ * ]
2. [ * ]
3. [ * ]
4. [ * ]
5. [ * ]
6. [ * ]
7. [ * ]
8. [ * ]

The Contractor will use the following subcontractors:

1. [ * ]
2. [ * ]

-------------

   [ * ] Confidential Treatment Requested

<PAGE>
     I.      KEY MEMBERS OF PROJECT TEAMS:

For LSO:
Project Director, SHI-SHI WANG, PH.D.
Project Manager, NANCY GLASER

For Contractor:
Project Director, KLEMENS SCHUETTE PH.D
Project Manager, DUBRAVKA PAVIC - SLADOLJEV, MD

     J.      TRANSFER OF OBLIGATIONS FORM:

LSO transfers to Contractor certain requirements of the US Food and Drug
Administration, as described in Appendix G-4.

     K.      OTHER:

For purposes of this IPA only, the Master Services Agreement effective
February 27, 2004 is hereby amended, as follows:

Section 1. Definitions
Section 1., Definitions, definition of "All Applicable Laws and Regulations" is
deleted in its entirety and the following section is "Applicable Laws and
Regulations" definition is inserted:

"All Applicable Laws and Regulations" means applicable federal, state,
provincial and local laws, orders, ordinances, policies, regulations, rules and
guidelines of any countries (including but not limited to the United States and
the European Union) having authority over any clinical studies conducted
hereunder, the use or review of data obtained as a result of such clinical
studies, or the activities of Ergomed in providing Services under this
Agreement. For clinical studies conducted under an investigational new drug
application and investigational device exemption filed in the United States,
Applicable Laws include, without limitation, 21 CFR Pts. 312, 812, 50, 54, and
56, the FDA's Electronic Records and Electronic Signatures Guidance (21 CFR Pt.
11), and the Health Insurance Portability and Accountability Act of 1996 and its
implementing regulations (45 CFR Pts. 160 and 164) ("HIPAA"), as amended from
time to time. For studies conducted in, or for use in an application for
marketing in the European Union or in any Member State of the European Union,
Applicable Laws and Regulations include, but are not limited to the Clinical
Trials Directive (2001/20/EC), The Medical Device Directive (93/42/EEC), the EU
Good Clinical Practice Guideline (Directive 2005/28/EC), and the Personal Data
Directive (95/46/EC). Applicable Laws and Regulations also include all
conditions of approval imposed by the

<PAGE>

reviewing IRB/Ethics Committees, FDA and other applicable authorities, ICH
guidelines (including the "Good Clinical Practice:

Consolidated Guideline") and the ethical principles contained in the Declaration
of Helsinki, as set forth in 21 CFR Section 312.120(c)(4), as amended from time
to time.

Section 10. Indemnification

Section 10., Indemnification, of the February 27, 2004 agreement between the
parties is amended, as follows:

The current Section 10 is renumbered to Section 10.1. and entitled, "LSO
Indemnification." and the following sentences are deleted: "The indemnifying
party will reimburse the indemnified party promptly upon invoicing for any
payment made by indemnified party in respect to any liability or claim to which
any indemnity obligation under this contract relates. The indemnified party will
give prompt notice to indemnifying party of any claim to which this paragraph
relates."

A new section 10.2, "Contractor Indemnification." is added:
Contractor will indemnify, pay the defense costs of, and hold harmless LSO and
its successors, officers, directors and employees and subcontractors from and
against any and all actions, causes of action, claims, demands, costs, losses,
liabilities, expenses, penalties, fines and damages (including, without
limitation, reasonable attorneys' fees) (collectively, "LSO Losses") arising out
of or in connection with any third party claim arising from (a) the actual or
alleged breach of any representations, warranties or obligations contained in
this Agreement; and (b) property damage or bodily injury (including death), if
and to the extent the same is attributable to the fault, negligence, gross
negligence, strict liability, willful misconduct, or intentional misconduct of
Contractor or any of its successors, officers, directors, employees, agents,
investigators, subcontractors or representatives, or the failure of Contractor
or any such person or entity to comply with this Agreement.

A new Section 10.3, "Procedure." is added:
Each party will give the indemnifying party (a) prompt written notice of any
claim for which it seeks indemnification hereunder; (b) all relevant facts in
its possession or control; (c) the right to control the defense and settlement
of any action unless the party being indemnified reasonably determines that a
conflict of interest exists with respect to such assumption of the defense due
to actual or potential differing interests between the parties or because of a
business relationship between the indemnifying party and the third party
claimant; and (d) cooperation in the defense and settlement of any such action
at the indemnifying party's expense. The indemnifying party will not settle any
third party claims without the prior written consent of the indemnified party,
not to be unreasonably withheld.

Section 14.  Notices

<PAGE>

The legal Notice information for LSO is deleted in its entirety and the
following is inserted:

For LSO:
Jay Winship, MD, FACP
Chief Operating Officer and Chief Medical Officer
3491 SE Douglas Street, Suite 250
Snoqualmie, WA 98065
USA
Phone:  425.369.2767
Fax:  425.392.7392

(Note: This is for legal notice provisions under the Master Service Agreement,
NOT for the monitoring, adverse event reporting, and communication with LSO
described in Section D. of this IPA.)

Upon the date of the last signature, below, this IPA is fully incorporated into
the Master Services Agreement effective February 27, 2004, and all Services and
Deliverables created in connection with this IPA are subject to the conditions
of the Master Services Agreement.

ACKNOWLEDGED AND AGREED TO:

LIGHT SCIENCES ONCOLOGY INC.

  /s/ Jay Winship, MD              3/1/01
-----------------------------------------
Jay Winship, MD, FACP
Chief Operating Officer, Chief Medical Officer

ERGOMED CLINICAL RESEARCH LTD.

 /s/ Miroslav Redonovic, MD       8th March, 2006
-------------------------------------------------
Miroslav Redonovic, MD
CEO

<PAGE>

                                  APPENDIX G-1

--------------------------------------------------------------------------------
A MULTICENTER MULTINATIONAL PHASE 3 RANDOMIZED STUDY TO EVALUATE THE SAFETY AND
EFFICACY OF TREATING COLORECTAL CANCER PATIENTS WITH RECURRENT LIVER METASTASES
USING THE LITX(TM) PLUS CHEMOTHERAPY AS COMPARED TO CHEMOTHERAPY ALONE
--------------------------------------------------------------------------------

STUDY PRODUCT:     Litx(TM) System

PROTOCOL NUMBER:   LSO-OL006

IND NUMBER:        37,088

STUDY SPONSOR:     Light Sciences Oncology
                   34931 SE Douglas St., Suite 250
                   Snoqualmie, WA 98065

Original protocol: February 28, 2006

--------------------------------------------------------------------------------
THE INFORMATION CONTAINED HEREIN IS THE PROPERTY OF LIGHT SCIENCES ONCOLOGY AND
IS CONFIDENTIAL. IT MAY BE SUBMITTED TO A REGULATORY AUTHORITY OR AN
INSTITUTIONAL REVIEW BOARD/ETHICAL COMMITTEE FOR THE PURPOSES OF ASSESSMENT IN
RELATION TO REGISTRATION OF THE PRODUCT OR INITIATION OF A CLINICAL TRIAL.
REPRODUCTION OR DISCLOSURE OF THE INFORMATION, IN WHOLE OR IN PART, OTHER THAN
FOR THE SAID PURPOSE, IS FORBIDDEN UNLESS AT THE EXPRESS REQUEST OR WITH THE
WRITTEN CONSENT OF THE PROPRIETOR.
--------------------------------------------------------------------------------
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<S>                                                                                 <C>
1      INVESTIGATOR AGREEMENT

2      SYNOPSIS

3      STUDY OBJECTIVES

4      BACKGROUND

    4.1   INTRODUCTION

    4.2   HEPATOCELLULAR CARCINOMA

    4.3   RATIONALE

5      PRODUCT INFORMATION

    5.1   LS11 DESCRIPTION

    5.2   LS11: CLINICAL USE AND HANDLING

    5.3   LIGHT SOURCES

    5.4   POWER CONTROLLER

6      ELIGIBILITY

    6.1   ELIGIBILITY CRITERIA

7      TREATMENT SCHEDULE

8      STUDY PROCEDURES

    8.1   SCREEN/BASELINE:

    8.2   TREATMENT: DAY 0

    8.3   [ * ]

    8.4   [ * ]

    8.5   [ * ]

    8.6   [ * ]

    8.7   [ * ]

    8.8   [ * ]

    8.9   [ * ]

    8.10  [ * ]

    8.11  [ * ]

    8.12  CHANGE IN TREATMENT

    8.13  RE-TREATMENT WEEKS

    8.14  DATA SAFETY MONITORING COMMITTEE (DSMC)

    8.15  SURVIVAL

    8.16  SCHEDULE OF EVENTS FROM BASELINE TO STUDY COMPLETED
</TABLE>

    [ * ]  Confidential Treatment Requested
<PAGE>
<TABLE>
<S>                                                                                 <C>
9      CRITERIA FOR EVALUATION

    9.1   STUDY ENDPOINTS

10     DATA MANAGEMENT AND STATISTICAL CONSIDERATIONS

    10.1  DATA COLLECTION MANAGEMENT AND ANALYSIS

11     PROTOCOL MANAGEMENT

    11.1  PATIENT SCREENING

    11.2  PATIENT REGISTRATION

    11.3  PROTOCOL ADHERENCE

    11.4  ACCURACY OF DATA COLLECTION

    11.5  CASE REPORT FORMS AND DATA ANALYSIS

12     REPORTING REQUIREMENTS FOR ADVERSE EVENTS

    12.1  DEFINITIONS

    12.2  REPORTING REQUIREMENTS

    12.3  CATEGORIES FOR RANKING SEVERITY OF AN ADVERSE EVENT

    12.4  CATEGORIES FOR DETERMINING RELATIONSHIP TO THE INVESTIGATIONAL PRODUCT

    12.5  REPORTING SERIOUS ADVERSE EVENTS

13     REGULATORY REQUIREMENTS

    13.1  INVESTIGATOR OBLIGATIONS

    13.2  INFORMED CONSENT

    13.3  INSTITUTIONAL REVIEW BOARD

14     ADMINISTRATIVE CONSIDERATIONS

    14.1  PRE-STUDY DOCUMENTATION

    14.2  STUDY DOCUMENTATION

    14.3  DATA COLLECTION

    14.4  PROTOCOL INTERPRETATION AND COMPLIANCE

    14.5  STUDY MONITORING

    14.6  DISCLOSURE OF DATA / PUBLICATION

15     REFERENCES

16     APPENDIX 1
</TABLE>

<PAGE>

                                  APPENDIX G-1

1 INVESTIGATOR AGREEMENT

I have read the proceeding protocol dated December 28, 2005:

"A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and
Efficacy of Treating Colorectal Cancer Patients with Recurrent Liver Metastases
using the Litx(TM) plus Chemotherapy as Compared to Chemotherapy Only" and agree
that it contains all necessary details for conducting the study.

I will conduct the study as outlined therein, in accordance with Good Clinical
Practices (GCPs) and the Declaration of Helsinki and comply with the obligations
and requirements of clinical investigators and all other requirements listed in
the International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) and Good Clinical Practice
(GCP). I will attempt to complete the planned enrollment of patients within
approximately one year of the receipt of clinical supplies.

I will provide copies of the protocol and all drug information relating to the
nonclinical and prior clinical experience, furnished to me by the Sponsor, to
all relevant staff/members. I will discuss this material with them to ensure
they are fully informed regarding the drug and the conduct of the study. I have
been explained the purpose of the Source Documentation Verification (SDV), and
fully understand this will be part of the monitoring process. I understand and
agree which items must be included in the source documents. All parties agree to
ensure direct access to examine, analyze, verify and reproduce source
data/documents, and reports from all trials related sites for the purpose of
monitoring and auditing by the Sponsor or the respective CRO that is managing
the site, and inspection by domestic and foreign regulatory authorities.

I agree to keep records on all patient information (Case Report Forms and
patient's informed consent statement), drug transportation and return forms, and
all other information collected during the study for a period of 2 years
following the date a marketing application is approved for the drug for the
indication for which it is being investigated; or, if no application is to be
filed or if the application is not approved for such indication, until 2 years
after the investigation is discontinued and the FDA or other regulatory
authorities are notified and I have received notification from Light Sciences
Oncology.

I agree not to publish all or any part of the results of the study carried out
under this protocol, without the prior written consent of Light Sciences
Oncology.

Investigator Name:
                   -------------------------
                            (Printed)

Signature:                                     Date:
           ---------------------------------         ------------------
                                                     (dd/mm/yy)

<PAGE>

                                  APPENDIX G-1

2 SYNOPSIS

<TABLE>
<S>                            <C>
Title of Study                 A Multicenter Multinational Phase 3 Randomized
                               Study to Evaluate the Safety and Efficacy of
                               Treating Colorectal Cancer Patients with
                               Recurrent Liver Metastases using the Litx(TM)
                               plus Chemotherapy as Compared to Chemotherapy
                               Only

Protocol Number                LSO-OL006

Investigator Countries         United States, Europe, and Asia

Indication                     Colorectal Cancer with recurrent liver metastases

Study Centers                  [ * ]

Number of Patients             [ * ]

Enrollment Duration            [ * ]
Study Duration

Objectives                     [ * ]

Eligibility Criteria           INCLUSION CRITERIA

                                    1.   Patients with recurrent metastatic
                                         liver lesions from colorectal cancer

                                    2.   Biopsy proven evidence of colorectal
                                         cancer

                                    3.   [ * ]

                                    4.   [ * ]

                                    5.   [ * ]

                                    6.   [ * ]

                                    7.   Understanding and ability to sign
                                         written informed consent.

                                    8.   [ * ]

                                    9.   [ * ]

                               EXCLUSION CRITERIA

                                    1.   Patients who are candidates for
                                         complete surgical resection

                                    2.   [ * ]

                                    3.   [ * ]

                                    4.   [ * ]

                                    5.   [ * ]

                                    6.   [ * ]

                                    7.   [ * ]

                                    8.   [ * ]

                                    9.   [ * ]

                                    10.  [ * ]
</TABLE>

----------
[ * ] Confidential Treatment Requested

<PAGE>

                                  APPENDIX G-1

<TABLE>
<S>                            <C>
                                    11.  [ * ]

                                    12.  [ * ]

Stratification and             Upon enrollment, patients will be stratified by
Randomization                  [ * ].

Light Source Placement         Light Source placement will be conducted under
                               ultrasound or CT guidance. [ * ].

Study Drug, Dose               LS11 (Talaporfin Sodium) presented as a
                               lyophilized powder for reconstitution. Each 10mL
                               vial contains 100 mg LS11 for reconstitution with
                               4 mL of 0.9% Sodium Chloride Injection USP to
                               give a solution at a concentration of 25 mg/mL.
                               [ * ].

Study Device                   Light Source was designed for percutaneous
                               placement under imaging guidance. [ * ].

Drug Light Interval            [ * ]

Duration of Light Activation   [ * ]

Imaging                        Independent radiologists will assess all CT
                               images. [ * ].

Chemotherapy for both groups   The standard chemotherapy is FOLFOX 4 or FOLFIRI.
                               [ * ].

Treatment                      Plan Patients who provide Informed Consent and
                               satisfy the Eligibility Criteria will be placed
                               in an eligibility pool for randomization for
                               either, Litx(TM) plus chemotherapy treatment arm
                               or the chemotherapy arm. [ * ].

                               [ * ]. The following table is a guide to a
                               suggested treatment plan:

                                                     [ * ].

                               All Study Patients:

                               [ * ].

                               The Study Design is outlined below.

                               [ * ] (5 pages)
</TABLE>

----------
[ * ] Confidential Treatment Requested

<PAGE>

                                  APPENDIX G-I

<TABLE>
<S>                            <C>
Change in Treatment for        A change in treatment may be considered if in the
either Litx(TM)+chemo or       investigators opinion there has been a treatment
chemo only group               failure of either Litx(TM)+chemo or chemo only as
                               defined as disease progression. [ * ].

Disease Progression using      Defined as [ * ].
modified RECIST criteria

Re-treatment Litx(TM)+chemo    [ * ]
Group

Survival                       All patients will be monitored for survival from
                               the time of randomization [ * ].

Data Safety Monitoring Board   [ * ]
(DSMB)

Criteria of Evaluation         [ * ]

Statistical Methodology        [ * ]
</TABLE>

3 STUDY OBJECTIVES

Assess the time to progression in patients [ * ].

Demonstrate the safety of Litx(TM) therapy.

Assess the survival of patients [ * ].

4 BACKGROUND

4.1 INTRODUCTION

This protocol is for a research study in patients with liver metastases from
colorectal cancer. This study is to be conducted according to U.S. and
International Standards of Good Clinical Practice (FDA Title 21 CFR part 312 and
International Conference on Harmonization guidelines), applicable government
regulations, and Institutional research polices and procedures.

4.2 LIVER METASTASES FROM COLORECTAL CANCER

Colorectal cancer is one of the most common malignancies in the world and the
second leading cause of cancer death in Western countries(1). More than 300,000
new cases of colorectal cancer occur each year in Europe and the United
States(2,3). Liver metastases form the main cause of death in patients with
colorectal cancer. Already at the time of detection of the primary tumor 15-25%
of the patients present with liver metastases, another 20% will develop these
metastases following treatment of the colorectal primary(4). Without any
treatment median survival after detection of liver metastases is approximately 9
months, depending on the extent of the disease at the time of diagnosis(5). In
patients with metastatic disease confined to the liver, resection of the
metastases offers the best chance of cure. After resection a 5-year survival
rate can be achieved of 35% - 40% depending on the extent of liver
involvement(6-9). Only a

----------
[ * ] Confidential Treatment Requested

<PAGE>

                                  APPENDIX G-I

minority (10% - 15%) of patients with liver metastases is however, considered
candidate for resection. In the majority of patients the liver metastases prove
unresectable.

In general, large tumors are difficult to operate on and less responsive to
chemotherapy and radiotherapy. Consequently, palliation of symptoms related to
increasing tumor load, and/or delay of the onset of the symptoms as well as
survival, are major clinical objectives in management of patients with advanced
cancers. Recent chemotherapy schedules combining fluorouracil (FU) and
oxaliplatin or irinotecan have considerably improved the results of systemic
chemotherapy in the palliative treatment of patients with metastatic colorectal
cancer in terms of the response rate, progression-free survival,(10-14) and
overall survival(11, 12, 14).

The management of these patients with liver metastases from colorectal cancer is
a therapeutic challenge. The need for well-tolerated, active interventions for
locoregional disease is clear. Light Infusion Technology or "Litx(TM)" has the
potential to significantly contribute to the fulfillment of this medical need.

Litx(TM) is a locoregional cancer treatment in which a systemically administered
photosensitizer is activated locally by illuminating the diseased tissue with
light of a specific wavelength. The activated photosensitizer reacts with
endogenous oxygen to yield a highly reactive species of oxygen (singlet oxygen)
that cause peroxidation of the cellular structures such as mitochondria,
lysosomes, and cell walls, leading to irreversible cell damage and tissue
necrosis(15).

[ * ].

In clinical studies thus far, LS11 has demonstrated to be well tolerated when
administered by intravenous injection. For more information see the Investigator
Brochure.

4.3 RATIONALE

RATIONALE FOR LS11 DOSE:

All patients in the Litx(TM) group will receive a 1 mg/kg intravenous dose of
LS11 based on previous clinical experience and registration of this drug dose in
Japan for early endobronchial cancer using a laser as the light energy source.

RATIONALE FOR LIGHT DOSE:

[ * ].

RATIONALE FOR DRUG-LIGHT INTERVAL (DLI):

[ * ].

RATIONALE FOR POSITIONING OF MULTIPLE LIGHT SOURCES:

[ * ].

----------
[ * ] Confidential Treatment Requested
<PAGE>

                                  APPENDIX G-1

LESION SIZE AND KILL ZONE:

[ * ].

RATIONALE FOR CHEMOTHERAPY:

[ * ].

4.4 SUGGESTED DRUG REGIMEN:

FOLFOX4:

<TABLE>
<S>            <C>
Oxaliplatin    85 mg/m(2)
Folinic Acid   200/100 mg/m(2)
Fluorouracil   400 mg/m(2) (IV Bolus)
Fluorouracil   600 mg/m(2)
</TABLE>

Repeat every 14 days for a maximum total of 12 cycles or disease progression
Some of the frequently occurring adverse events include:

     -    Nausea

     -    Vomiting

     -    Diarrhea

     -    Stomatitis

     -    Neutropenia

     -    Thrombocytopenia

FOLFIRI

<TABLE>
<S>            <C>
Irinotecan     180 mg/m(2)
Folinic Acid   400/200 mg/m(2)
Fluorouracil   400 - 500 mg/m(2) (IV Bolus)
               Then
Fluorouracil   2400 - 3000 mg/m(2)
</TABLE>

Repeat every 14 days until disease progression Some of the frequently occurring
adverse events include:

     -    Nausea

     -    Vomiting

     -    Diarrhea

     -    Stomatitis

     -    Myelosuppression

RATIONALE FOR RE-TREATMENT:

[ * ].

----------
[ * ] Confidential Treatment Requested

<PAGE>

                                  APPENDIX G-1

5 PRODUCT INFORMATION

5.1 LS11 DESCRIPTION

LS11 (mono-L-aspartyl chlorin e(6)) is a chemically synthesized photosensitizer
with a molecular weight of 799.69.

                             (MOLECULAR STRUCTURE)

LS11 appears as a dark blue-green powder. The absorption spectrum of LS11
exhibits a maximum peak at 664 nm in an UV-visible absorption spectrum when LS11
is incubated with PtK2 cells, or when it is mixed with bovine serum albumin at a
molar ratio of 1:1 in phosphate buffer solution of pH 7.4. LS11 has been shown
to be stable for a minimum of 2.5 years when stored in sealed containers at
2-8 degrees C protected from light.

Light Sciences Oncology supplies LS11 as a lyophilized powder in 10 mL clear
vials, each containing 100 mg drug product. Each vial is individually packaged
in a carton. For more information please refer to the Investigator Brochure.

5.2 LS11: CLINICAL USE AND HANDLING

5.2.1 VIAL LABELING

Each LS11 vial and single vial carton has a label containing the following
information:

For IV Use Only

100 mg/vial

Lot number and expiration date

Keep Refrigerated. Store between 2-8 degrees C

Protect from Light

Caution: New Drug - Limited by Federal Law to Investigational Use

Use within 8 hours of Reconstitution

<PAGE>
5.2.2 SHIPPING TO CLINICAL SITES

[ * ].

5.2.3 STORAGE OF LS11

[ * ].

5.2.4 DOSE CALCULATION

[ * ].

5.2.5 PREPARATION OF THE SOLUTION

[ * ].

5.2.6 LS11 ADMINISTRATION

Since compatibility between LS11 and other drugs is not established, LS11 should
not be mixed with or physically added to other drugs.

[ * ].

5.2.7 POTENTIAL ADVERSE EVENTS

[ * ].

5.2.8 RETURN OF DRUG

All used vials will be retained in the institution's pharmacy until the Clinical
Research Associate performs a complete drug accountability audit. Following this
accounting used vials may be discarded according to hospital policy or may be
returned to an LSO designated vendor for destruction.

5.3 LIGHT SOURCES

5.3.1 DESCRIPTION

The Light Sciences Oncology Light Source consists of a Light Bar at the distal
end of the Light Source catheter and a Power Controller attached to the catheter
at the proximal end. The disposable Light Source is battery powered and emits a
broad band of wavelength, which peaks [ * ].

The Power Controller supplies an isolated low voltage power to the Light Source
and provides internal continuous monitoring of performance. It is designed and
tested to comply with IEC 60601-1 medical device safety standards.

Detailed specifications for the disposable Light Source(s) and Power Controller
are described in the Litx(TM) System Operator's Manual provided by Light
Sciences Oncology.

5.3.2 CLINICAL USE AND HANDLING

[ * ].  It is recommended that the Light Source be placed as follows: [ * ].

-------------

      [ * ]  Confidential Treatment Requested

<PAGE>

5.3.3 LABELING

Light Source pouch including Power Controller labeling includes the
following information:

Investigational Device, Contents and Property of.

5.3.4 SHIPPING TO CLINICAL SITES

      During manufacturing, the Light Sources are individually packed inside a
sterile pouch, which is then placed inside a protective box. Upon shipment
request from Light Sciences Oncology or its designated representative, the
distribution service provider will pull the appropriate number of boxes and
properly prepare them for shipment to the institution. The package will be
shipped via traceable means to arrive at the site within the time frame
requested.

5.3.5 STORAGE

[ * ].

5.3.6 DISPOSAL OF USED LIGHT SOURCES

Upon completion of each Litx(TM) treatment as outlined in Section 7 of this
protocol, the explanted disposable Light Source and Power Controller should be
disposed, as per the institutions standard operating procedures.

5.3.7 PRECAUTIONS OF LIGHT SOURCES

The Light Source should not be used with Magnetic Resonance Imaging (MRI), as
the system has not been verified to be MRI safe.

Follow universal infection control precautions when inserting and maintaining
the Light Source in the tumor.

The Light Sources and Power Controller are for one time use only. Do not attempt
to retreat the devices will not function.

5.4 INTRODUCER

5.4.1 DESCRIPTION

[ * ].

Detailed specifications for the Introducer are described in the LitxTM System
Operator's Manual provided by Light Sciences Oncology.

5.4.2 CLINICAL USE AND HANDLING

The Introducer is provided as a single use only device in a single barrier
sterile pouch. [ * ].

-------------

      [ * ]  Confidential Treatment Requested

<PAGE>

5.4.3 LABELING

Introducer pouch labeling includes the following information:
Investigational Device, Contents and Property of.

5.4.4 SHIPPING TO CLINICAL SITES

[ * ].

5.4.5 STORAGE

[ * ].

5.4.6 DISPOSAL OF USED INTRODUCERS

Upon completion of each Litx(TM) treatment as outline in Section 7 of this
protocol, the explanted Introducer should be disposed of as specified per the
institutions standard operating procedures.

5.4.7 PRECAUTIONS OF INTRODUCERS

The Light Source should not be used with MRI due to the metallic nature of the
trocar. Follow universal infection control precautions when inserting and
maintaining the sheath in the tumor.

-------------

      [ * ]  Confidential Treatment Requested

<PAGE>

6   ELIGIBILITY

6.1  INCLUSION CRITERIA

1.    [ * ]

2.    [ * ]

3.    [ * ]

4.    [ * ]

5.    [ * ]

6.    [ * ]

7.    Understanding and ability to sign written informed consent

8.    [ * ]

9.    [ * ]

6.2  EXCLUSION CRITERIA

1.    Patients who are candidates for complete surgical resection

      [ * ]

-------------

      [ * ] Confidential Treatment Requested
<PAGE>

                                  APPENDIX G-1

7 TREATMENT SCHEDULE

Eligible patients will be treated according to the schedule shown in Table
8.16-1.

[ * ].

7.1 SUGGESTED LITX(TM) TREATMENT PLAN

[ * ].

8 STUDY PROCEDURES

8.1 SCREEN/BASELINE:

[ * ].

8.2 TREATMENT: DAY 0

8.2.1 LITX(TM)+CHEMO GROUP:

[ * ].

8.2.2 CHEMO ONLY GROUP:

[ * ]. (4 pages)

8.2.13 CHANGE IN TREATMENT

[ * ].

8.2.14 RE-TREATMENT WEEKS

8.2.15 LITX(TM)+CHEMO GROUP

[ * ].

8.2.16 DATA SAFETY MONITORING COMMITTEE (DSMC)

[ * ].

8.2.17 SURVIVAL

All patients will be followed for survival [ * ].

----------
[ * ] Confidential Treatment Requested

<PAGE>

                                  APPENDIX G-1

8.2.18 SCHEDULE OF EVENTS FROM BASELINE TO STUDY COMPLETED

[ * ].

9. IMAGING RESPONSE

9.1 IMAGING DEFINITIONS

[ * ].

9.1.1 RESPONSE

[ * ].

9.1.2 COMPLETE RESPONSE

[ * ].

9.1.3 PARTIAL RESPONSE

[ * ].

9.1.4 STABLE DISEASE

[ * ].

9.1.5 DISEASE PROGRESSION

10 REPORTING REQUIREMENTS FOR ADVERSE EVENTS

10.1 DEFINITIONS

An adverse event is any undesirable experience concerning the health of a
patient occurring during a clinical trial. This is whether or not the adverse
event is considered related to the study treatments, such as events not reported
at baseline, intercurrent illnesses, hypersensitivity reactions, toxicity,
injuries, and clinically relevant laboratory abnormalities.

A Serious Adverse Event (SAE) is any adverse drug/device experience occurring at
any dose that results in any of the following outcomes:

Death;

Life-threatening adverse drug/device experience;

Inpatient hospitalization or prolongation of existing hospitalization;

A persistent or significant disability/incapacity;

A congenital anomaly/birth defect;

----------
[ * ] Confidential Treatment Requested

<PAGE>

                                  APPENDIX G-1

Important medical events that may not result in death, be life-threatening, or
require hospitalization may be considered a serious adverse drug experience
when, based upon appropriate medical judgment, they may jeopardize the patient
and may require medical or surgical intervention to prevent one of the outcomes
listed in this definition.

10.2 REPORTING REQUIREMENTS

10.2.1 DEFINITION OF SERIOUS ADVERSE EVENTS (SAES)

All serious adverse events during the study period, whether or not considered to
be related to study treatment must be reported to the respective CRO that is
managing the site within 24 hours or, at the latest, on the following working
day.

At the time of the initial report, as much information as possible should be
provided: patient allocation number, treatment, study identifiers, the phase of
treatment during which the event occurred, a description of the event, its date
of onset and current status; the start date, the start time, whether this
treatment has been discontinued; the reason why the event is regarded as
serious; the current assessment of causality, investigator's name and address.

The investigator must fax the SAE form within the next 24 hours if it is not
provided at the time of the initial notification. Any other diagnostic
information, which will assist the understanding of the event, should be
provided at this time.

The study patient must be followed until the final outcome of the SAE is known,
including any which are still ongoing at the end of the study. Significant new
information on the SAE, and the final outcome, must be supplied promptly to the
respective CRO that is managing the site. This should be done in the same way
and time frame as for the original notification, using the SAE form and
identifying this as follow up information.

The investigator must report promptly any SAEs, which may be detected after the
study, and are suspected to be related to study treatment.

Investigators must report all SAEs to the IRB according to their institutional
policy.

10.2.2 NON-SERIOUS ADVERSE EVENTS

All non-serious adverse events reported or observed, and the remedial action
required will be recorded in the patient's Case Report Form. The Case Report
Form must have all relevant fields completed.

10.3 CATEGORIES FOR RANKING SEVERITY OF AN ADVERSE EVENT

National Cancer Institute Common Terminology Criteria for Adverse Events v3.0
(CTCAE) will be used to categorize adverse events and to score severity. A copy
of the criteria is presented in Appendix 1. The following definitions will
assist in scoring adverse events.
<PAGE>

                                  APPENDIX G-1

          Grade 1   Mild, easily tolerated by the patient, causing minimal
                    discomfort and not interfering with everyday activities.

          Grade 2   Moderate, sufficiently discomforting to interfere with
                    normal everyday activities.

          Grade 3   Severe, prevents normal everyday activities.

          Grade 4   Life threatening, places the patient at immediate risk of
                    death.

          Grade 5   Death

10.4 CATEGORIES FOR DETERMINING RELATIONSHIP TO THE INVESTIGATIONAL PRODUCT

The causality assessment to be used to record the relationship between the study
treatment (drug related or device related) and the adverse event are as follows:

     None:       The temporal relationship of the clinical event to the study
                 treatment (drug related or device related) makes a causal
                 relationship unlikely, or

                 other drugs, therapeutic interventions or underlying conditions
                 provide a sufficient explanation for the observed event.

     Probable:   The temporal relationship of the clinical event to study
                 treatment (drug related or device related) makes a causal
                 relationship probable, and other drugs, therapeutic
                 interventions or underlying conditions do not provide a
                 definitive explanation for the observed event.

     Definite:   The temporal relationship of the clinical event to study
                 treatment (drug related or device related) makes a causal
                 relationship definite, and other drugs, therapeutic
                 interventions or underlying conditions can provide a definitive
                 explanation for the observed event.

10.5 REPORTING SERIOUS ADVERSE EVENTS

All serious adverse events during the study period, whether or not considered to
be related to study treatment must be reported to the respective CRO that is
managing the site within 24 hours or, at the latest, on the following working
day.

At the time of the initial report, as much information as possible should be
provided: patient allocation number, treatment, study identifiers, the phase of
treatment during which the event occurred, a description of the event, its date
of onset and current status; the start date, the start time, whether this
treatment has been discontinued; the reason why the event is regarded as
serious; the current assessment of causality, investigator's name and address.

The investigator must fax the SAE form within the next 24 hours if it is not
provided at the time of the initial notification. Any other diagnostic
information, which will assist the understanding of the event should be provided
at this time.

The study patient has to be followed until the final outcome of the SAE is
known, including any which are still ongoing at the end of the study.
Significant new information on the SAE, and the final outcome, must be supplied
promptly to the

<PAGE>

                                  APPENDIX G-1

respective CRO that is managing the site. This should be done in the same way
and time frame as for the original notification, using the SAE form and
identifying this as follow up information.

The investigator must report promptly any SAEs, which may be detected after the
study, and are suspected to be related to study treatment.

Investigators must report all SAEs to the IRB according to their institutional
policy.

11 REGULATORY REQUIREMENTS

11.1 INVESTIGATOR OBLIGATIONS

As indicated on FDA Form 1572, the Principal Investigator is responsible for
ensuring that all study site personnel, including Sub-Investigators and other
study staff members, adhere to all FDA regulations and guidelines regarding
clinical trials both during and after study completion.

11.2 INFORMED CONSENT

All patients will be informed of the nature of the program, its possible
hazards, and their right to withdraw at any time, and will sign a form
indicating their consent to participate. Each institution's Informed Consent
Form must be reviewed and approved by its designated Institutional Review Board
and by LSO clinical staff.

11.3 INSTITUTIONAL REVIEW BOARD

This protocol and relevant supporting data are to be submitted to the
appropriate Institutional Review Board (IRB) for review and approval before the
study can be initiated. Amendments to the protocol will also be submitted to the
IRB prior to implementation of the change. The Sponsor must receive a letter
documenting the IRB approval prior to initiation of the study. The Principal
Investigator is also responsible for informing the IRB of the progress of the
study and for obtaining annual IRB renewal. The IRB must be informed at the time
of completion of the study and should be provided with a summary of the results
of the study by the Principal Investigator. The Principal Investigator must
notify the IRB in writing of any serious adverse event or any unexpected adverse
event according to FDA guidelines.

12 ADMINISTRATIVE CONSIDERATIONS

12.1 PRE-STUDY DOCUMENTATION

Light Science Oncology must receive the following documentation prior to
initiation of the trial:

FDA form 1572 signed by the Principal Investigator (PI);

Curriculum vitae of the PI and all sub-investigators;

Signed protocol agreement;

Copy of the informed consent form that was reviewed and approved by the IRB;

Copy of IRB approval letter;

<PAGE>

                                  APPENDIX G-1

Financial disclosures of the PI and all sub-investigators;

Normal reference ranges and laboratory accreditation.

12.2 STUDY DOCUMENTATION

The Principal Investigator and study staff has the responsibility of maintaining
a comprehensive and centralized filing system containing all study related
documentation. These files must be suitable for inspection by LSO or the FDA at
any time, and should consist of the following elements:

Patient files, containing the completed medical records, laboratory data,
supporting source documentation, and the informed consent;

Study files, containing the protocol with all amendments, copies of all
regulatory documentation, and all correspondence between the IRB and Sponsor;

Drug accountability files, containing a complete account of the receipt and
disposition of the drug and device.

Records are to be available for two years after marketing application approval,
or if the application is not approved or never submitted, two years after the
last shipment and delivery of the material and the FDA is so notified. The files
should not be destroyed until the official termination letter from the Light
Science Oncology.

12.3 DATA COLLECTION

Case Report Forms (CRFs) are to be completed in a neat, legible manner, using a
black or blue pen, to ensure accurate interpretation of data. Any changes or
corrections made on the CRFs must be dated and initialed by the individual who
is authorized to make the change. When corrections are made, the original entry
should be crossed out using a single line. Do not erase or overwrite the
original entry. All blanks on the CRFs must be filled in.

12.4 PROTOCOL INTERPRETATION AND COMPLIANCE

The Principal Investigator and staff, prior to the time of study initiation, to
ensure accurate interpretation and implementation, will carefully review the
procedures defined in the protocol.

12.5 STUDY MONITORING

A representative from Light Sciences Oncology or designated CRO will visit the
study center periodically to monitor adherence to the protocol, adherence to
applicable FDA regulations, and the maintenance of adequate and accurate
clinical records. CRFs will be reviewed to ensure that key safety and efficacy
data are collected and recorded as specified by the protocol. The LSO or
designated CRO representative will be permitted to access patient medical
records, laboratory data, and other source documentation as needed to
appropriately monitor the trial. The Investigator should allocate adequate time
for these visits.

12.6 DISCLOSURE OF DATA / PUBLICATION

No part of the results of the study carried out under this protocol, or any of
the

<PAGE>

                                  APPENDIX G-1

information provided by Light Sciences Oncology to the investigator for the
purposes of performing the study, will be published, or passed on to a third
party, without prior review by Light Sciences Oncology. The Principal
Investigator or anyone else working on the study will submit all proposed
publications, papers, abstracts or other written materials related to the Study,
or an outline of any proposed oral presentation with respect, to Light Sciences
Oncology at least one month prior to (i) submission of such written materials
for publication, or (ii) any proposed oral disclosure to a third party. Light
Sciences Oncology shall have the right to comment on such written material or
outline; the Principal Investigator in determining the final form of disclosure
shall consider such comments in good faith. Notwithstanding any of the above,
the Principal Investigator or anyone else working on the Study may not include
any confidential information in any such publication or disclosure.

The Investigator is obliged to provide Light Sciences Oncology with complete
test results and all data derived from the study. Only LSO and its authorized
CRO may make information obtained during the study available to regulatory
agencies, except as required by regulation.

<PAGE>

                                  APPENDIX G-1

13 REFERENCES

1.   Efficace, F., A. Bottomley, V. Vanvoorden, and J. M. Blazeby. 2004.
     Methodological issues in assessing health-related quality of life of
     colorectal cancer patients in randomised controlled trials. Eur J Cancer
     40:187-197.

2.   Black, R. J., F. Bray, J. Ferlay, and D. M. Parkin. 1997. Cancer incidence
     and mortality in the European Union: cancer registry data and estimates of
     national incidence for 1990. Eur J Cancer 33:1075-1107.

3.   Landis, S. H., T. Murray, S. Bolden, and P. A. Wingo. 1999. Cancer
     statistics, 1999. CA Cancer J Clin 49:8-31, 31.

4.   Scheele, J., R. Stangl, and A. Altendorf-Hofmann. 1990. Hepatic metastases
     from colorectal carcinoma: impact of surgical resection on the natural
     history. Br J Surg 77:1241-1246.

5.   Stangl, R., A. Altendorf-Hofmann, R. M. Charnley, and J. Scheele. 1994.
     Factors influencing the natural history of colorectal liver metastases.
     Lancet 343:1405-1410.

6.   Fong, Y., A. M. Cohen, J. G. Fortner, W. E. Enker, A. D. Turnbull, D. G.
     Coit, A. M. Marrero, M. Prasad, L. H. Blumgart, and M. F. Brennan. 1997.
     Liver resection for colorectal metastases. J Clin Oncol 15:938-946.

7.   Hughes, K. S., R. Simon, S. Songhorabodi, M. A. Adson, D. M. Ilstrup, J. G.
     Fortner, B. J. Maclean, J. H. Foster, J. M. Daly, D. Fitzherbert, and et
     al. 1986. Resection of the liver for colorectal carcinoma metastases: a
     multi-institutional study of patterns of recurrence. Surgery 100:278-284.

8.   Nordlinger, B., M. Guiguet, J. C. Vaillant, P. Balladur, K. Boudjema, P.
     Bachellier, and D. Jaeck. 1996. Surgical resection of colorectal carcinoma
     metastases to the liver. A prognostic scoring system to improve case
     selection, based on 1568 patients. Association Francaise de Chirurgie.
     Cancer 77:1254-1262.

9.   Scheele, J., R. Stang, A. Altendorf-Hofmann, and M. Paul. 1995. Resection
     of colorectal liver metastases. World J Surg 19:59-71.

10.  de Gramont, A., A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C.
     Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail,
     C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan, and A. Bonetti.
     2000. Leucovorin and fluorouracil with or without oxaliplatin as first-line
     treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947.

11.  Douillard, J. Y., D. Cunningham, A. D. Roth, M. Navarro, R. D. James, P.
     Karasek, P. Jandik, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad,
     and P. Rougier. 2000. Irinotecan combined with fluorouracil compared with
     fluorouracil alone as first-line treatment for metastatic colorectal
     cancer: a multicentre randomised trial. Lancet 355:1041-1047.

12.  Saltz, L. B., J. V. Cox, C. Blanke, L. S. Rosen, L. Fehrenbacher, M. J.
     Moore, J. A. Maroun, S. P. Ackland, P. K. Locker, N. Pirotta, G. L.
     Elfring, and L. L. Miller. 2000. Irinotecan plus fluorouracil and
     leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl
     J Med 343:905-914.

13.  Tournigand, C., T. Andre, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard,
     E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet,
     and A.

<PAGE>

                                  APPENDIX G-1

     de Gramont. 2004. FOLFIRI followed by FOLFOX6 or the reverse sequence in
     advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol
     22:229-237.

14.  Goldberg, R. M., D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K.
     Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and S. R.
     Alberts. 2004. A randomized controlled trial of fluorouracil plus
     leucovorin, irinotecan, and oxaliplatin combinations in patients with
     previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30.

15.  Henderson, B. W., and T. J. Dougherty. 1992. How does photodynamic therapy
     work? Photochem Photobiol 55:145-157.

16.  Kessel, D. 1997. Pharmacokinetics of N-aspartyl chlorin e6 in cancer
     patients. J Photochem Photobiol B 39:81-83.

17.  Data on File. In Control Document # 810-0019. Light Sciences Oncology.

<PAGE>

                                  APPENDIX G-2

                  GENERAL TEMPLATE CLINICAL RESEARCH AGREEMENT
                        ERGOMED-INVESTIGATOR/INSTITUTION

This AGREEMENT is made on this __________________________________________

BETWEEN:

ERGOMED CLINICAL RESEARCH LTD.
1 Frederick Sanger Rd.
Surrey Research Park
Guildford, Surrey, GU2 7YD,
U.K. (hereinafter referred to as ERGOMED)

AND

___________________________________ (full name of the Institution)

___________________________________ (full address)

___________________________________

___________________________________

(hereinafter referred to as the INSTITUTION)

___________________________________

AND

___________________________________ (name of the Investigator)

with business address at:

___________________________________

___________________________________

___________________________________

___________________________________

(hereinafter referred to as the INVESTIGATOR)

___________________________________
WHEREAS:

ERGOMED and _________________________________________ (hereinafter the
"Sponsor") have concluded a Clinical Trial Agreement by which ERGOMED undertook
to carry out the following clinical trial:
"_________________________________________________ (hereinafter: "the Clinical
Trial") and agreed to undertake other necessary activities for preparing the
Clinical Trial;

and

ERGOMED wishes to involve the INSTITUTION and INVESTIGATOR in the Clinical Trial
in the role referred to herein and the INSTITUTION and INVESTIGATOR accept such
involvement.

<PAGE>

                                                                               1

WHEREBY IT IS AGREED AS FOLLOWS:

                                   ARTICLE 1.

                                  DEFINITIONS

1.1. For the purpose of this Agreement, the following expressions shall have the
     meanings attributed to them below:

<TABLE>
<S>                    <C>
the "Clinical Trial"   the clinical trial referred to and described in the
                       Protocol

the "Product"          (state the full name of the substance /product to be used
                       in research)

the "Protocol"         (state the full name of Protocol) (alternative: name of
                       the Protocol, as attached herein as Schedule 1 and as
                       approved and amended from time to time by the Sponsor)

"Recruitment Period"   (in studies where this is a relevant element -- state the
                       date(s) during which or by which the recruitment is to be
                       fully completed or refer to the Recruitment Plan, if
                       there is such Plan)

the "Services"         the services of research and other similar services to be
                       performed by the INVESTIGATOR at the INSTITUTION with a
                       primary purpose of testing the Product pursuant to the
                       Protocol.
</TABLE>

                                   ARTICLE 2.

                      RIGHTS AND OBLIGATIONS OF THE PARTIES

2.1. Pursuant to the terms and conditions of this Agreement, INSTITUTION,
     through the efforts of INVESTIGATOR, agrees to conduct the Clinical Trial
     in __________ patients according to the Protocol. By signing the Agreement
     INVESTIGATOR acknowledges that (s)he has received and reviewed the full
     text of Protocol (as herein attached).

2.2. INSTITUTION and INVESTIGATOR agree to perform the work required under the
     Protocol and this Agreement and to conduct the Clinical Trial with
     reasonable care and skill and in accordance with the Protocol, agreed
     Standard Operating Procedures and the GCP regulations (see Note for
     Guidance Good Clinical Practice [CPMP/ICH/135/95] and Guideline for Good
     Clinical Practice [ICHE6] Step 4, Consolidated Guideline, 1.05.96, in its
     then valid version, respectively.

2.3. INVESTIGATOR shall obtain any and all licenses, permits, approvals, and
     patient informed consent documents required for conducting of the relevant
     part of the Clinical Trial from the INSTITUTION and/or any other authorized
     body and ICH and GCP guidelines.

2.4. INSTITUTION and INVESTIGATOR will arrange for any other relevant personnel
     required to carry out the Protocol and shall ensure that at all times
     during the Clinical Trial there is enough personnel to support the Clinical
     Trial.

2.5. ERGOMED may, at its sole option, arrange for the availability of a study
     coordinator, duly qualified by training and / or experience, to manage some
     administrative functions at the site.

<PAGE>

                                                                               2

2.6. INSTITUTION and INVESTIGATOR shall perform the Clinical Trial efficiently
     and within the time frames set out in this Agreement and the Protocol.
     INSTITUTION and INVESTIGATOR agree that the time is of essence for the
     purposes of this Agreement.

2.7. INVESTIGATOR shall personally conduct the Clinical Trial and supervise the
     work of all the involved personnel. INVESTIGATOR shall not delegate his/her
     obligations from this Agreement to any third party without the prior
     written approval of ERGOMED.

2.8. The parties understand and agree that any alteration or amendment to either
     the attached Protocol or this Agreement must be approved in writing by the
     Sponsor prior to such alteration or amendment becoming effective.

                                   ARTICLE 3.

                            COMPENSATION AND EXPENSES

3.1. As compensation for the conduct of the Clinical Trial as referred to in
     this Agreement ERGOMED shall pay to the INSTITUTION the gross fee indicated
     in Schedule II (Schedule I if no Protocol is attached) herein attached and
     made an integral part of this Agreement. This gross fee includes any and
     all taxes that may be applicable anywhere anytime and it is specifically
     agreed that any such taxes shall be the sole responsibility of the
     INSTITUTION.

3.2. It is agreed that payment of the sums due under this Agreement shall be
     payable by ERGOMED by an international check or by wire transfer at the
     bank account indicated in the INSTITUTION's invoice.

3.3. Unless otherwise agreed in writing and approved by Sponsor, payments of the
     sums due under this Agreement shall be made according to the attached
     Schedule II (Schedule I if no Protocol is attached).

3.4. In undertaking to perform professional services for ERGOMED, it is
     understood that INVESTIGATOR is doing so as an employee of the INSTITUTION
     and not as an employee of ERGOMED.

                                   ARTICLE 4.

                              INTELLECTUAL PROPERTY

4.1. The parties hereby agree that ERGOMED and/or the Sponsor shall at all times
     retain ownership of all intellectual property resulting from the Clinical
     Trial or the Clinical Trial and the INSTITUTION and INVESTIGATOR have no
     rights to any such intellectual property. For the avoidance of doubt, the
     INSTITUTION and INVESTIGATOR hereby grant to Sponsor any and all right,
     title and interest in any and to any invention, discovery or improvement
     conceived or reduced to practice in connection with the Clinical Trial or
     the Clinical Trial.

4.2. The parties agree the INSTITUTION and INVESTIGATOR assert no claim to
     rights in technology and materials owned by ERGOMED or the Sponsor.

4.3. INSTITUTION or INVESTIGATOR may be allowed to present and publish data
     resulting from the Clinical Trial pursuant to the Sponsor's publication
     policies and upon obtaining prior written approval from the Sponsor for any
     such presentation or publication. In case of presentation or publication of
     such data INSTITUTION and INVESTIGATOR shall be bound by the
     confidentiality clause from Article 5. of this Agreement and subject to
     preserving Sponsor's

<PAGE>

                                                                               3

     rights in Sections 4.1 and 4.2. The provisions of this Article 4 shall
     survive termination or expiration of this Agreement.

                                   ARTICLE 5.

                                 CONFIDENTIALITY

5.1. INSTITUTION and INVESTIGATOR shall hold in strict confidence any and all
     information acquired by the INSTITUTION and/or INVESTIGATOR from ERGOMED
     and/or the Sponsor in reference to this Agreement or the Clinical Trial or
     developed by him/her with regard to the Clinical Trial or the Product.

5.2. INSTITUTION and / or INVESTIGATOR undertake to permit access to the
     Confidential Information only to those employees of the INSTITUTION or
     members of the INVESTIGATOR'S team who reasonably need access to such
     information for the carrying out of the duties under this Agreement.
     Furthermore, such access to Confidential Information shall be permitted
     only on condition that such employees have entered into legally binding
     confidentiality agreement with terms equivalent to those stipulated herein
     and have been instructed to treat the confidential information as such in
     accordance with the provisions of this Agreement.

5.3. This Clause shall not apply to information:

     a)   which was known to INSTITUTION or INVESTIGATOR prior to its receipt
          from ERGOMED or the Sponsor, and INSTITUTION or INVESTIGATOR is able
          to so demonstrate through bona fide written records of such receipt,

     b)   which is or lawfully becomes generally available to the public as
          evidenced by objective public record,

     c)   which is lawfully acquired from third parties who have a right to
          disclose such information, or

     d)   which INSTITUTION or INVESTIGATOR is required by law to release,
          provided that INSTITUTION or INVESTIGATOR gives advance written notice
          of such requirement so that Sponsor has the opportunity to object to
          such disclosure.

5.4. Nothing herein shall be construed as prohibiting the Sponsor from reporting
     on this Clinical Trial to a governmental agency or from exercising its
     publication rights as stated in Section 4.3.

5.5. The terms of this Article 5. and the parties' obligations hereunder shall
     survive termination or expiration of this Agreement.

                                   ARTICLE 6.

                              TERM AND TERMINATION

6.1. This Agreement shall become effective on the date first written above and
     shall remain in full force and effect until the full and satisfactory
     completion of the Services by the INSTITUTION and INVESTIGATOR.

6.2. ERGOMED may terminate this Agreement prior to the full and satisfactory
     completion of the Services by the INSTITUTION and INVESTIGATOR by written
     notice and immediate effect for

<PAGE>

                                                                               4

     any of the following reasons:

     A.   Notice received by ERGOMED that the Sponsor has terminated the
          relevant Agreement with ERGOMED and / or has ceased any further
          activity on the Clinical Trial regardless of the reason given to
          ERGOMED by the Sponsor;

     B.   Notification received by the Sponsor from Regulatory Authorities to
          terminate the Clinical Trial;

     C.   Continuous and / or repetitive and /or material breach of any of the
          INSTITUTIONS and / or INVESTIGATOR's obligations stipulated herein;

     D.   In case INVESTIGATOR does not recruit any patient within _____ days
          from the day of the initial visit;

     E.   In case INVESTIGATOR delegates any of his/her obligations from this
          Agreement without the prior written approval by ERGOMED in breach of
          Article 2.7. herein;

     F.   Determination by ERGOMED and/or the Sponsor that the INVESTIGATOR,
          after a reasonable opportunity, is unable, for any reason, to
          satisfactorily perform the Clinical Trial as required by the Protocol
          and a suitable replacement is not made;

     G.   Case Report Forms, to be completed by the INVESTIGATOR pursuant to
          ERGOMED's and/or the Sponsor's request, have not been legibly
          completed and / or forwarded by the INVESTIGATOR to ERGOMED or to its
          designated representative, as appropriate, within 60 days of each
          patient's completion date;

     H.   INVESTIGATOR and/or INSTITUTION prevent access to ERGOMED's employees
          or contractors or any third persons authorized by ERGOMED and / or the
          Sponsor to any and all original medical records necessary to verify
          entries on Clinical Trial Case Report Forms;

     I.   INVESTIGATOR, his/her associates, or any other person engaged in this
          Clinical Trial (excluding patients) are unavailable upon reasonable
          notice by ERGOMED and/or the Sponsor, to meet with an ERGOMED's and/or
          the Sponsor's representative during the course of the Clinical Trial,
          as necessary, to discuss information relevant to the Clinical Trial;

     J.   Determination by the Sponsor that business or scientific
          considerations require termination of the Clinical Trial;

     K.   INSTITUTION and/or INVESTIGATOR do not comply with all regulatory
          requirements;

     L.   INVESTIGATOR ceases to be employed with the INSTITUTION.

6.3. In the event that ERGOMED chooses to exercise its right to terminate this
     Agreement in line with Article 6.2. of this Agreement, the INVESTIGATOR
     shall, immediately upon receipt of ERGOMED's notice to terminate, cease
     enrolling patients into the Clinical Trial and shall discontinue conducting
     Clinical Trial procedures, to the extent medically possible.

6.4. Any rights that any party might have obtained during the term of this
     Agreement will survive such termination until the complete fulfillment of
     such rights, or as otherwise provided.

6.5. In the event of early termination, the sum payable under this Agreement
     shall be limited to pro-rated fees based on actual work performed pursuant
     to the Protocol.

<PAGE>

                                                                               5

6.6. The INSTITUTION and INVESTIGATOR shall return to ERGOMED the Product and
     all Clinical Trial materials immediately upon termination but in any case
     no later than within one month from the termination of the Agreement.

                                   ARTICLE 7.

                                FINAL PROVISIONS

7.1. None of the parties may delegate their obligations or assign their rights
     hereunder without the prior written consent of the Sponsor.

7.2. Any and all additions and/or amendments to this Agreement shall be in
     writing, numbered, dated and signed by the authorized representatives of
     both parties.

7.3. Any and all disputes arising out of or in connection with the Agreement
     shall be settled by an amicable effort of the parties.

7.4. Any dispute, which is not amicably settled by such efforts of the Parties,
     shall be finally resolved under the Rules of the Chartered Institute of
     International Arbitration in London, England, UK, by 1 (one) arbitrator
     appointed pursuant to such Rules. The seat of such arbitration shall be in
     London, UK.

7.5. This Agreement and all disputes thereof shall be governed by and construed
     in accordance with the substantive laws of England.

7.6. If any provision of this Agreement should be deemed invalid or legally
     unenforceable, such provision shall not affect the validity and/or
     enforceability of any other provision(s) of this Agreement or the Agreement
     as a whole. The parties shall, in such case, replace the invalid provision
     with a valid one that best expresses their original intent.

7.7. This Agreement is being executed in 3 (three) identical copies, of which
     each party shall keep 1 (one) copy.

SIGNED on behalf of ERGOMED:

-------------------------------------   ----------------------------------------
                                        Date

SIGNED by the INSTITUTION:

-------------------------------------   ----------------------------------------
                                        Date

SIGNED by the INVESTIGATOR:

-------------------------------------   ----------------------------------------
                                        Date

<PAGE>

                                                                               6

                    SCHEDULE I - THE PROTOCOL (IF APPLICABLE)

<PAGE>

                                                                               7

                         SCHEDULE II - BUDGET AND TIMING

<TABLE>
<S>     <C>    <C>

</TABLE>

<PAGE>

                                                                               8

                SCHEDULE III - RECRUITMENT PLAN (WHEN APPLICABLE)

<PAGE>

                                  APPENDIX G-3

<PAGE>

(ERGOMED LOGO)

REVISED BUDGET FOR MCRC TRIAL, [ * ].

<TABLE>
<CAPTION>
                                                      Unit
                                           Unit       Cost             Total
               Activity                Description   (EUR)   # Units   (EUR)
               --------                -----------   -----   -------   -----
<S>                                    <C>           <C>     <C>       <C>
Preparation
                                          [ * ]

Subtotal Preparation                                                   [ * ]
Set up & Pre-Trial activity
                                          [ * ]

Subtotal Set up & Pre-Trial activity                                   [ * ]
Study Conduct
                                          [ * ]

Subtotal Study Conduct                                                 [ * ]
Training
                                          [ * ]

Subtotal Training                                                      [ * ]
Pharmacovigilance
                                          [ * ]

Subtotal Pharmacovigilance                                             [ * ]
Regulatory
                                          [ * ]
</TABLE>

----------
[ * ] Confidential Treatment Requested

                                     Page 1

<PAGE>

<TABLE>
<S>                                    <C>           <C>     <C>       <C>
                                                                       [ * ]
Subtotal Regulatory
Data Management
                                          [ * ]
Subtotal Data Management                                               [ * ]
Study Physician
                                          [ * ]
Subtotal Study Physician                                               [ * ]
Project Management
                                          [ * ]

Subtotal Project Management                                            [ * ]
Administrative support
                                          [ * ]
Subtotal Project Management                                            [ * ]
TOTAL EURO                                                             [ * ]
</TABLE>

<TABLE>
<CAPTION>
                Unit Cost                Total
 Other costs      (EUR)     # Units      (EUR)
 -----------    ---------   -------   ----------
<S>             <C>         <C>       <C>
Site Payments
                  [ * ]
Other
                  [ * ]

TOTAL EURO                               [ * ]
                                      10.154.328
                                      22565,1722
</TABLE>

----------
[ * ] Confidential Treatment Requested

                                     Page 2

<PAGE>

                                  APPENDIX G-4

                                                                   MARCH 9, 2006

DR. RICHARD PAZDUR, MD
DIRECTOR, DIVISION OF ONCOLOGY PRODUCTS
U.S. FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
5901-B AMMENDALE RD.
BELTSVILLE, MD. 20705-1266

RE: TRANSFER OF SPONSOR OBLIGATIONS TO A CONTRACT RESEARCH ORGANIZATION,
EUROPEAN AND USA SITES, IND NO. 37,088, LS11, FORMERLY NPE6 (TAPORFIN SODIUM)

Dear Dr. Pazdur,

In accordance with 21 CFR Part 312.52, Light Sciences Oncology, holder of the
above referenced IND, doing business at 34931 S.E. Douglas Street, Suite 250,
Snoqualmie, WA 98065 is notifying you that certain sponsor obligations related
to IND 37,088 for the conduct of the study entitled:

     "A MUTICENTER MULTINATIONAL PHASE 3 RANDOMIZED STUDY TO EVALUATE THE SAFETY
     AND EFFICACY OF TREATING COLORECTAL CANCER PATIENTS WITH RECURRENT LIVER
     METASTASES USING THE LITX(TM) PLUS CHEMOTHERAPY AS COMPARED TO CHEMOTHERAPY
     ALONE"

have been transferred to:

     ERGOMED CLINICAL RESEARCH, LTD.
     1 FREDERICK SANGER RD.
     SURREY RESEARCH PARK
     GUILDFORD, SURREY, GU2 7YD
     U.K.

The specific sponsor obligations hereby transferred for the conduct of the above
referenced study at European sites to ERGOMED CLINICAL RESEARCH, LTD. are as
follows:

Selection of investigators in Europe and the USA

     -    Control of Drug in Europe and the USA

                                        1

<PAGE>

     -    Before permitting an investigator to begin participation in an
          investigation, ERGOMED CLINICAL RESEARCH, LTD. shall obtain the
          following information

          (1)  A signed investigator statement (FDA form FD-1572)

          (2)  Curriculum vitae(s) of all European investigators and
               sub-investigators

          (3)  Financial disclosure information

     -    Selection of Monitors in Europe and USA

     -    Prior to the start of any investigation, ERGOMED CLINICAL RESEARCH,
          LTD. will give each participating European and USA clinical
          investigator a copy of the investigator Brochure (IB) containing
          information required under 21 CFR Part 312.23(a)(5).

     -    ERGOMED CLINICAL RESEARCH, LTD. will keep each participating European
          and USA investigator informed during the course of the investigation
          of new observations discovered by or reported to the sponsor about the
          drug, particularly with respect to adverse drug effects and safe use.

     -    ERGOMED CLINICAL RESEARCH, LTD. will monitor all Adverse Drug
          Experiences (ADRs) occurring in Europe and USA and submit to FDA all
          reports of such Adverse Drug Experiences.

     -    ERGOMED CLINICAL RESEARCH, LTD. will monitor the progress of all
          clinical investigations in Europe and USA being conducted under IND
          37,088.

     -    If ERGOMED CLINICAL RESEARCH, LTD. discovers that a European or USA
          investigator is not in compliance with the signed agreement (FDA form
          FD-1572), the investigational plan or the requirements of the
          applicable regulations, ERGOMED CLINICAL RESEARCH, LTD. will promptly
          attempt to secure the investigator's compliance or discontinue
          European or USA shipments of the investigational drug and device
          products to the European or American investigator and end the
          participation of the investigator in the study. If the investigator's
          participation is ended, ERGOMED CLINICAL RESEARCH, LTD. will secure
          the disposition of all unused European or USA investigational products
          and return the investigational product in compliance to 21 CFR Part
          312.59 and also notify FDA.

     -    ERGOMED CLINICAL RESEARCH, LTD. will maintain adequate records showing
          the receipt, shipment, and all other dispositions of the European and
          USA investigational products. The records will include the name of the
          European and USA investigator to whom the products are shipped
          including the date, quantity and batch or identifying code number/mark
          of each shipment.

     -    ERGOMED CLINICAL RESEARCH, LTD. will retain records for the
          transferred responsibilities for at least 2 years as required under
          the regulations after the application is approved or, if the
          application is not approved until 2 years after the

                                       2

<PAGE>

          last shipment of the investigational items is discontinued and upon
          FDA notification.

     -    ERGOMED CLINICAL RESEARCH, LTD. will ensure the return of all unused
          European clinical supplies of investigational products from each
          European and USA investigator whose participation in the study is
          discontinued. ERGOMED CLINICAL RESEARCH, LTD. may authorize
          alternative disposition of unused European or USA supplies provided
          the alternative does not expose humans to risks from the drug.

     -    ERGOMED CLINICAL RESEARCH, LTD. will maintain written records of any
          European or USA disposition of the drug in accordance with 21 CFR Part
          312.57

If you have any questions, please contact me at your earliest convenience.

Sincerely,

Susan Wray Spraitzar, DDS, JD
Sr. Director, Legal and Regulatory Affairs

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]